Recombinant protein for cell therapy
By combining Cre recombinase with NS3 protease, a fusion protein was constructed and regulated using a protease inhibitor. This solved the problems of activation efficiency and background leakage in gene expression regulation of the Cre recombinase system, achieving efficient and stable gene expression regulation, which is suitable for gene function research and cell therapy.
Patent Information
- Application Number
- PCT/CN2026/096969
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Existing Cre recombinase systems suffer from problems such as low activation efficiency, severe background leakage expression, non-specific effects of inducers, and unstable regulatory responses in gene expression regulation, which affect their reliability and practicality in complex physiological environments.
A fusion protein was constructed by using a specific combination of Cre recombinase and NS3 protease, which includes the N-terminal fragment of the recombinase, the restriction site, and the C-terminal fragment of the protease. The activity of the fusion protein was regulated by protease inhibitors to achieve efficient recombination and stable expression regulation.
It achieves high recombinant activity, low background expression, and good induction response characteristics in animal cells, improving the system's regulatory specificity and response rate, and is suitable for gene function research, transgenic model construction, and cell therapy.
Smart Images

Figure PCTCN2026096969-FTAPPB-I100001 
Figure PCTCN2026096969-FTAPPB-I100002 
Figure PCTCN2026096969-FTAPPB-I100003
Abstract
Description
Recombinant proteins for cell therapy Technical Field
[0001] This application relates to the field of biomedicine, specifically to a tunable recombinase system and its applications. Background Technology
[0002] With the continuous development of molecular biology and genetic engineering, gene expression regulation systems have become important tools for regulating the function of specific genes. By precisely controlling the expression level of target genes, researchers can simulate physiological or pathological states, study gene function, establish animal models, and achieve personalized regulation in clinical fields such as cell therapy and gene therapy.
[0003] For example, in stem cell-derived cell therapy, regulating the expression level of target genes can endow stem cells and their derived cells or adult cells with characteristics such as immune concealment, enhanced function, improved targeting, and enhanced survival, thereby significantly improving therapeutic efficacy. However, inappropriate timing or lack of regulation of gene expression at the pluripotent stem cell stage may trigger a series of negative effects, such as impaired pluripotency, apoptosis, spontaneous differentiation, differentiation arrest, and difficulty in functional verification, ultimately affecting the therapeutic potential and efficacy of the cells. Therefore, constructing a controllable gene expression regulation system is of great significance.
[0004] In existing technologies, the Cre / lox system is a widely used site-specific recombination system, extensively applied in gene knockout, expression regulation, and cell tracing. To regulate the Cre recombinase system, researchers have developed various regulatory strategies, including Cre-ER (estrogen receptor fusion), Tet-on / off systems, doxycycline-induced systems, and light-controlled systems. However, these existing controllable Cre recombinase systems still face many limitations in practical applications. For example, they suffer from low activation efficiency, severe background leakage expression, non-specific effects of inducers, difficulty in achieving rapid on / off switching, and unstable regulatory responses, severely impacting their reliability and practicality under complex physiological environments. Therefore, constructing a controllable and efficient Cre recombinase system is of great significance. Summary of the Invention
[0005] The purpose of this invention is to provide a novel, regulated Cre recombinase system / strategy that can significantly reduce background expression and enhance regulatory specificity while maintaining high recombination activity, and exhibits good system adaptability and regulatory response rate in animal cells. This system can be widely applied in various scenarios such as gene function research, transgenic model construction, and cell therapy development, possessing significant technical advantages and application value.
[0006] Furthermore, through extensive experimental research, the applicant unexpectedly discovered that the superior regulatory effect of the aforementioned modulotropic Cre recombinase system / strategy stems from a specific combination formed between Cre recombinase and NS3 protease, rather than a simple substitution of a single element. Specifically, in the system constructed in this invention, the combination of Cre and NS3 can simultaneously achieve high recombination efficiency, low background leakage, and good induction response characteristics, thereby realizing a stable and controllable expression regulation effect.
[0007] In contrast, when Cre recombinase is replaced with other recombinases (e.g., Dre recombinase), and / or NS3 protease is replaced with other protease systems (e.g., 3CLpro), the resulting systems fail to achieve the comprehensive technical effects achieved by this invention. For example, some replacement systems failed to observe the expected induced expression regulation, exhibiting persistently low levels of expression; others showed significant spontaneous expression or background leakage problems, meaning that unexpected expression activation occurred even without induction, thereby reducing the system's regulatory specificity and controllability.
[0008] To achieve the above objectives, the present invention provides a fusion protein comprising an N-terminal fragment of a recombinase, an enzyme cleavage site, a protease, and a C-terminal fragment of a recombinase.
[0009] In some embodiments, the fusion protein comprises, from the N-terminus to the C-terminus:
[0010] a) N-terminal fragment of recombinase, restriction site, protease, C-terminal fragment of recombinase;
[0011] b) N-terminal fragment of recombinase, protease, restriction site, C-terminal fragment of recombinase; or
[0012] c) Recombinase N-terminal fragment, restriction site, protease, restriction site, recombinase C-terminal fragment.
[0013] In some embodiments, the recombinase is selected from one or more recombinases from the group consisting of Cre recombinase, Flp recombinase, and Dre recombinase.
[0014] In some embodiments, the recombinase is a Cre recombinase.
[0015] In some embodiments, the cleavage sites of the N-terminal and C-terminal fragments of the recombinase are located in the loop-connecting region of the Crease.
[0016] In some embodiments, the Cre recombinase comprises the amino acid sequence shown in SEQ ID NO:22.
[0017] In some embodiments, the cleavage sites of the N-terminal and C-terminal fragments of the recombinase are: between amino acid residues at positions 59 and 60, 104 and 106, 155 and 156, 180 and 196, 232 and 233, or 244 and 245 from the N-terminus.
[0018] In some embodiments, the splitting sites of the N-terminal and C-terminal fragments of the recombinase are, with reference to the Cre recombinase sequence shown in SEQ ID NO:22, between amino acid residues 59 and 60, 104 and 106, 155 and 156, 180 and 196, 232 and 233, or 244 and 245 from the N-terminus.
[0019] In some embodiments, the cleavage sites of the N-terminal and C-terminal fragments of the recombinase are between amino acid residues 59 and 60 or 244 and 245 from the N-terminus.
[0020] In some embodiments, the protease is a viral protease that can be used for protein cleavage or degradation.
[0021] In some embodiments, the protease is selected from one or more proteases from the group consisting of NS3 protease, TEV protease, and 3C / 3CL protease.
[0022] In some embodiments, the protease is NS3 protease.
[0023] In some embodiments, the NS3 protease comprises the amino acid sequence shown in SEQ ID NO:23.
[0024] In some embodiments, the N-terminal fragment of the recombinase, the restriction site, the protease, and any two adjacent fragments of the C-terminal fragment of the recombinase are directly linked.
[0025] In some embodiments, the N-terminal fragment of the recombinase, the restriction site, the protease, and any two adjacent fragments of the C-terminal fragment of the recombinase are connected by one or more linkers.
[0026] In some embodiments, the recombinant protein comprises, from N-terminus to C-terminus, the following:
[0027] a) N-terminal fragment of recombinase, linker, restriction site, linker, protease, linker, C-terminal fragment of recombinase;
[0028] b) N-terminal fragment of recombinase, linker, protease, linker, restriction site, linker, C-terminal fragment of recombinase; or
[0029] c) Recombinase N-terminal fragment, linker, restriction site, linker, protease, linker, restriction site, linker, recombinase C-terminal fragment.
[0030] In some embodiments, the linker comprises the amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:25.
[0031] In some embodiments, the fusion protein comprises the amino acid sequence shown in SEQ ID NO:1 or SEQ ID NO:3.
[0032] In some implementations, the activity of the protease can be inhibited by a protease inhibitor to regulate the activity of the fusion protein.
[0033] In some embodiments, the protease inhibitor is an NS3 protease inhibitor selected from one or more of the following groups of inhibitors: Grazoprevir (GZV), Asunaprevir (ASV), Glecaprevir (GLE), Daclatasvir (DCV), Telaprevir (TPV), Danoprevir (DAV), Vaniprevir (VAV), Ciluprevir (BILN 2061), Simeprevir (SMV), Boceprevir (BOC), Sovaprevir (SOV), and Paritaprevir (PTV).
[0034] In some embodiments, the NS3 protease inhibitor is an ASV.
[0035] On the other hand, the present invention provides a polypeptide comprising the aforementioned fusion protein.
[0036] On the other hand, the present invention provides an isolated nucleic acid molecule that encodes the fusion protein or the polypeptide described herein.
[0037] On the other hand, the present invention provides a carrier containing the isolated nucleic acid molecules.
[0038] On the other hand, the present invention provides a gene expression regulation system, the expression regulation system comprising:
[0039] a) the fusion protein, the polypeptide, the isolated nucleic acid molecule, or the vector;
[0040] b) A gene expression regulatory cassette, comprising nucleic acid sequences encoding a target gene, a first lox site, and a second lox site, wherein the first lox site and the second lox site are oriented in the same direction and are not adjacent.
[0041] In some embodiments, a termination element is further included between the first lox site and the second lox site, the termination element including a transcription termination sequence, a polyadenylated sequence and / or a translation repressor sequence, and different copy numbers of the above sequences.
[0042] In some embodiments, the gene expression regulatory cassette further includes a promoter, and the gene expression regulatory system comprises, from the 5' end to the 3' end, the following:
[0043] Promoter, first lox site, terminator, second lox site, and target gene.
[0044] In some embodiments, the transcription termination sequence is SEQ ID NO:26.
[0045] In some embodiments, the nucleic acid sequences of the first lox site, the termination element, and the second lox site in the gene expression regulatory cassette, from the 5' end to the 3' end, comprise the sequence shown in SEQ ID NO:10.
[0046] In some embodiments, the first lox site and the second lox site contain a portion or the full-length coding sequence of the target gene.
[0047] In some embodiments, the coding sequence of the partial or full-length target gene includes the exon coding sequence of the target gene.
[0048] In some implementations, the first lox site and the second lox site are independently selected from wild-type loxP sites and mutated lox sites.
[0049] In some embodiments, the mutated lox site is selected from one or more sites from the group consisting of: LoxN site, Lox2272 site, Lox511 site, Lox5171 site, LoxM2 site, Lox66 site, and Lox71 site.
[0050] On the other hand, the present invention provides a cell comprising the fusion protein, the polypeptide, the isolated nucleic acid molecule, the vector, or the gene expression regulation system.
[0051] In some embodiments, the cells include pluripotent stem cells, adult stem cells, immune cells, nerve cells, and / or endocrine cells.
[0052] In some embodiments, the pluripotent stem cells are selected from one or more cells from the group consisting of embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), pluripotent stem cells similar to pluripotent stem cells (PLSCs), and extended pluripotent stem cells (EPSCs).
[0053] In some embodiments, the adult stem cells are selected from one or more cells from the group consisting of hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), neural stem cells (NSCs), epidermal stem cells (EpSCs), and pancreatic stem cells (PSCs).
[0054] In some embodiments, the immune cells are selected from one or more cells from the group consisting of T lymphocytes, macrophages, NK cells, and NKT cells.
[0055] In some embodiments, the endocrine cells are pancreatic β cells.
[0056] In some embodiments, the nerve cells are dopamine nerve cells.
[0057] On the other hand, the present invention provides a method for regulating a target gene, the method comprising: adding a protease inhibitor to the cell to regulate the activity of the fusion protein, thereby regulating the expression or silencing of the target gene.
[0058] In some embodiments, the protease inhibitor is an NS3 protease inhibitor selected from one or more of the following groups of inhibitors: Grazoprevir (GZV), Asunaprevir (ASV), Glecaprevir (GLE), Daclatasvir (DCV), Telaprevir (TPV), Danoprevir (DAV), Vaniprevir (VAV), Ciluprevir (BILN 2061), Simeprevir (SMV), Boceprevir (BOC), Sovaprevir (SOV), and Paritaprevir (PTV).
[0059] In some embodiments, the NS3 protease inhibitor is an ASV.
[0060] In some embodiments, the method is an in vitro or ex vivo method.
[0061] On the other hand, the present invention provides the use of the fusion protein, the polypeptide, the isolated nucleic acid, the vector, the gene expression regulation system, the cell, and the method thereof in the preparation of a drug for the prevention and / or treatment of a disease.
[0062] In some embodiments, the diseases include, but are not limited to, hematologic malignancies, solid tumors, autoimmune diseases, endocrine and metabolic diseases, nervous system diseases, respiratory diseases, inflammatory diseases, and infectious diseases.
[0063] In some embodiments, the autoimmune diseases include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; the endocrine diseases include, but are not limited to, diabetes; the neurological diseases include, but are not limited to, Parkinson's disease and Alzheimer's disease; the respiratory diseases include, but are not limited to, pneumonia and pulmonary fibrosis; and the inflammatory diseases include osteoarthritis.
[0064] Other aspects and advantages of this application will readily be apparent to those skilled in the art from the detailed description below. Only exemplary embodiments of this application are shown and described in the following detailed description. As will be appreciated by those skilled in the art, the content of this application enables them to make modifications to the disclosed specific embodiments without departing from the spirit and scope of the invention to which this application pertains. Accordingly, the descriptions in the accompanying drawings and specification of this application are merely exemplary and not restrictive. Attached Figure Description
[0065] The features and advantages of the invention related to this application can be better understood by referring to the exemplary embodiments and accompanying drawings described in detail below. A brief description of the drawings is as follows:
[0066] Figure 1. Effect of ASV treatment on cell proliferation.
[0067] Figure 2 shows the construction of reporter cell lines for gene expression control systems 1 (Figure 2A) and 2 (Figure 2B).
[0068] Figure 3 shows the test of GFP gene expression on an ES using gene expression control system 1.
[0069] Figure 4 shows the test of GFP gene expression on ES using gene expression control system 2.
[0070] Figure 5 shows the cell line construction of the TGFBRc gene expression control system 2.
[0071] Figure 6 shows the test of TGFBRc gene expression on an ES using gene expression control system 2.
[0072] Figure 7 shows the cell line construction of BCMA.CAR gene expression control system 2.
[0073] Figure 8 shows the test of BCMA.CAR gene expression on an ES using gene expression control system 2.
[0074] Figure 9 shows the test of BCMA.CAR gene expression during the differentiation of ES to NK stage using gene expression control system 2.
[0075] Figure 10 shows the detection of BCMA.CAR gene expression on an ES using a stable gene expression system.
[0076] Figure 11 shows the maturity (Figure 11A) and survival assessment (Figure 11B) of the BCMA.CAR gene expression control system 2 during the differentiation of ES into NK cells.
[0077] Figure 12 shows the maturity (Figure 12A) and viability assessment (Figure 12B) of the BCMA.CAR gene stable expression system during the differentiation of ES into NK cells.
[0078] Figure 13 shows the BCMA expression levels of Jeko-1 (Figure 13A), U266 (Figure 13B), and K562 (Figure 13C).
[0079] Figure 14 shows the in vitro killing effect of ES-NK derived from the BCMA.CAR gene expression control system 2 and the stable expression system on K562 cells under the conditions of an effector-to-target ratio (E:T) of 1 (Figure 14A) and an effector-to-target ratio (E:T) of 3 (Figure 14B).
[0080] Figure 15 shows the in vitro killing effect of ES-NK derived from the BCMA.CAR gene expression control system 2 and the stable expression system on Jeko-1 cells under the conditions of an effector-to-target ratio (E:T) of 1 (Figure 15A) and an effector-to-target ratio (E:T) of 3 (Figure 15B).
[0081] Figure 16 shows the in vitro killing effect of ES-NK derived from the BCMA.CAR gene expression control system 2 and the stable expression system on U266 cells under the conditions of an effector-to-target ratio (E:T) of 1 (Figure 16A) and an effector-to-target ratio (E:T) of 3 (Figure 16B).
[0082] Figure 17 shows the effect of TGFβ on ES-NK function.
[0083] Figure 18. Tolerance of ES-NK cells from the TGFBRc gene expression control system 2 to TGFβ treatment.
[0084] Figure 19 shows the administration (Figure 19A) and treatment of ES-NK derived from BCMA.CAR gene expression control system 2 to the Jeko-1 tumor model (in vivo optical imaging system, IVIS) (Figure 19B).
[0085] Figure 20. Treatment of Jeko-1 tumor model with ES-NK derived from BCMA.CAR gene expression control system 2 (IVIS luminescence intensity).
[0086] Figure 21 shows the pharmacokinetic (PK) profile of ES-NK derived from the BCMA.CAR gene expression control and stable expression system in the Jeko-1 tumor model.
[0087] Figure 22 shows a schematic diagram of the components of the GFP gene expression control system 1, 2, 3 or 4, divided into Part 1 and Part 2.
[0088] Figure 23 is a schematic diagram of the components of the BCMA.CAR gene expression control system 2, which is divided into part 1 (Figure 23A) and part 2 (Figure 23B).
[0089] Figure 24 shows a schematic diagram of the components of the TGFBRc gene expression control system 2, which is divided into part 1 (Figure 24A) and part 2 (Figure 24B).
[0090] Figure 25 shows a schematic diagram of the components of the GFP gene expression control system 5 or 6, divided into Part 1 and Part 2.
[0091] Figure 26 shows the cell line construction of the GFP gene expression control system 3.
[0092] Figure 27 shows the test of GFP gene expression on an ES using gene expression control system 3.
[0093] Figure 28 shows the effect of gene expression regulation systems 1, 2 and 3 on the expression induction of the GFP gene.
[0094] Figure 29 shows the cell line construction of the GFP gene expression control system 4.
[0095] Figure 30 shows the cell line construction of the GFP gene expression control system 5.
[0096] Figure 31 shows the test of GFP gene expression on an ES using the gene expression control system 5.
[0097] Figure 32 shows the cell line construction of the GFP gene expression control system 6.
[0098] Figure 33 shows the test of GFP gene expression on an ES using the gene expression control system 6.
[0099] Figure 34 shows the effect of different NS3 protease small molecule inhibitors on the expression induction of the GFP gene by the gene expression control system 2. Detailed Implementation
[0100] The following specific embodiments illustrate the implementation of the invention. Those skilled in the art can easily understand other advantages and effects of the invention from the content disclosed in this specification.
[0101] Terminology Definition
[0102] In this application, the term "fusion protein" refers to a single polypeptide chain comprising two or more protein or peptide components, wherein each component may be a non-covalently bound or non-binding molecule in its natural state, but can be linked and co-expressed by coding sequences through molecular biology, genetic engineering, or protein engineering techniques to form a fusion construct with a continuous amino acid sequence. The components can be linked by direct peptide bonds or indirectly through linkers, spacer peptides, flexible or rigid linker domains, restriction enzyme recognition sites, tag sequences, or other designable linker sequences. The fusion protein is not limited to the linking order or direction and may include various conformations such as N-terminal to C-terminal, C-terminal to N-terminal, central insertion, or bidirectional docking. In some embodiments, the fusion protein may comprise two or more recombinase fragments, a protease, and its corresponding restriction enzyme sites.
[0103] In this invention, the term "recombinase" refers to an enzyme or protein with similar function capable of catalyzing sequence rearrangement, integration, excision, insertion, or inversion between specific sites. The recombinase includes naturally derived, artificially modified site-specific recombinases. The recombinase can recognize naturally occurring or artificially designed recognition sites, acting on homologous or non-homologous nucleic acid sequences. The recombinase can exist alone or be fused with other functional structures to achieve condition-dependent regulation; these functional structures can be drug-inducible structures, photosensitizers, tags, localization signals, activation domains, etc. In some embodiments, the recombinase can be Cre recombinase, Dre recombinase, or Flp recombinase.
[0104] In this invention, the term "Cre recombinase" or "Cre enzyme" generally refers to a class of site-specific DNA recombinases capable of recognizing and acting on specific lox sites and catalyzing the recombination of nucleic acid sequences between said lox sites, wherein said specific lox sites include LoxP and its functionally equivalent variants. The Cre recombinase has the ability to catalyze the cutting, ligation, integration, insertion, deletion, inversion, circularization, reconstruction, or other forms of sequence rearrangement of DNA molecules. The Cre recombinase includes, but is not limited to, wild-type Cre enzymes, and all forms of engineered derivatives thereof, such as functionally preserved or enhanced mutants, structurally optimized forms, fusion protein forms, regulated structures, etc.
[0105] In this invention, a "split site" refers to a specific amino acid sequence or domain whose position and characteristics allow a target protein to be split into two or more fragments. After the target protein is split at the split site, it can be recombined to restore its activity. The split site can be a naturally occurring amino acid sequence or an artificially designed linker peptide sequence. In this application, when descriptions such as "the split site is located between positions 244 and 245 of SEQ ID NO:22" are used, it should be understood that the definition of the split site is not strictly limited to the exact same sequence shown in SEQ ID NO:22. Those skilled in the art can make appropriate modifications to the sequence, such as sequence lengthening, shortening, insertion, deletion, substitution, or mutation modification. As long as the modified sequence can still be identified by those skilled in the art as corresponding to the corresponding region in the sequence shown in SEQ ID NO:22, it should be considered to fall within the protection scope of the split site described in this invention.
[0106] In this invention, a "loop linker" or "loop linker" refers to a flexible domain in a protein or polypeptide sequence. This flexible domain is typically located between two functional segments or domains and provides spatial adaptability through irregular secondary structures (e.g., random coils or β-turns). The loop linker region can serve as a carrier region for protein cleavage sites, meaning it may contain specific amino acid sequences or structural features that allow the protein to be cleaved into N-terminal and C-terminal fragments at that location.
[0107] In this invention, "viral protease" refers to a class of proteolytic enzymes derived from viral genome-encoded products, capable of catalyzing the cleavage of specific peptide bonds. The protease, depending on its catalytic mechanism, may include serine, cysteine, aspartic, metalloproteinases, or other types. The viral protease encompasses naturally occurring viral proteases, as well as their functional variants, domain-truncate forms, artificially optimized mutants, fusion protein forms, and other viral protease derivatives. The viral protease can recognize natural or artificially designed cleavage sites, including but not limited to short peptide sequences and chimeric sequences. In some embodiments, the viral protease may be NS3 protease, TEV protease, and 3C / 3CL protease.
[0108] In this invention, the terms "NS3 protease," "NS3," or "non-structural protein 3" refer to a serine protease derived from the non-structural protein 3 region of a virus. The NS3 protease may contain a cofactor polypeptide that can activate protease hydrolysis activity, such as a cofactor polypeptide derived from HCV non-structural protein 4A (NS4A), for example, activating the NS4A region. The NS3 protease may be derived from hepatitis C virus (HCV). The NS3 protease may contain a serine protease domain at its N-terminus and may contain a helicase and a nucleoside triphosphatase at its C-terminus. The NS3 protease can mediate site-specific protein cleavage. The NS3 protease includes wild-type NS3 protease, as well as its functional variants, conserved mutants, fusion proteins, truncated forms, optimized or artificially designed mutants, as long as they retain the ability to catalyze specific protease hydrolysis reactions. The NS3 protease can recognize natural cleavage sites and can also recognize artificially designed cleavage sites, including but not limited to short peptide sequences, chimeric sequences, engineered linkers, and artificially positioned tag sequences.
[0109] In this invention, the term "NS3 protease inhibitor" refers to any form of chemical molecule, biological macromolecule, or complex construct capable of inhibiting or reducing the activity of NS3 protease. The NS3 protease inhibitor can inhibit NS3 protease-mediated proteolytic reactions by binding to the active site, substrate binding site, or structural regulatory region of the NS3 protease. The inhibitor includes, but is not limited to, small molecule compounds, peptides, proteins, antibodies, antibody fragments, nucleic acid molecules, and pharmaceutically acceptable salts, esters, prodrugs, metabolites, etc. The inhibitor can be reversible or irreversible, competitive or non-competitive. The inhibitor can also be an inhibitory element or a functional module with similar function. The inhibitor includes specific or broad-spectrum inhibitors against natural NS3 protease, structural variants, mutants, fusion proteins, or genetically engineered NS3. In some embodiments, the NS3 protease inhibitor may be Grazoprevir (GZV), Asunaprevir (ASV), Glecaprevir (GLE), Daclatasvir (DCV), Telaprevir (TPV), Danoprevir (DAV), Vaniprevir (VAV), Ciluprevir (BILN 2061), Simeprevir (SMV), Boceprevir (BOC), Sovaprevir (SOV), or Paritaprevir (PTV).
[0110] In this invention, the term "linker" refers to a structural element used to connect two or more functional molecules (such as proteins, peptides, nucleic acids, chemical groups, etc.). The linker functions, including but not limited to, providing spatial flexibility, reducing steric hindrance, maintaining molecular conformation, optimizing biological activity, or improving molecular stability. The linker may be composed of amino acids, nucleotides, synthetic polymers, or other biocompatible materials. The linker can be designed as a flexible, rigid, enzymatically degradable, or chemically stable structure. The linkers of this invention include natural, mutant, artificially optimized, or synthetically designed linker sequences. In some embodiments, the linker is a flexible linker, typically composed of small, neutral, hydrophilic amino acids (such as glycine and serine) repeating to provide high degrees of freedom and low structural constraints. In some embodiments, the linker may be GGSGGS (SEQ ID NO:24) or (GGSGGS). n , where n is a positive integer. In some embodiments, the connector can be GGGGS (SEQ ID NO:25) or (GGGGS). n , where n is a positive integer.
[0111] In this invention, the term "Lox site" refers to a specific DNA sequence that can be recognized and cleaved by recombinases. This site can form a complex with a recombinase, promoting DNA recombination reactions, including but not limited to deletions, insertions, inversions, or rearrangements. The Lox sites described in this invention can be used in conjunction with other DNA recombinases such as Cre recombinase and Flp recombinase to achieve gene knockout, gene editing, and gene regulation through DNA recombination reactions. The Lox sites described in this invention include wild-type LoxP sites or other mutant Lox sites, including but not limited to LoxN sites, Lox2272 sites, Lox511 sites, Lox5171 sites, LoxM2 sites, Lox66 sites, and Lox71 sites.
[0112] In this invention, the term "gene expression regulatory cassette" refers to an artificially constructed nucleic acid sequence containing regulatory elements and coding sequences, capable of regulating the expression of a target gene under specific conditions. The regulatory cassette can be integrated into the host cell genome or exist in a non-integrated form and is used to regulate gene function in vivo or in vitro. In some embodiments, the gene expression regulatory cassette includes at least: a) a nucleic acid sequence encoding the target gene; b) two unidirectional and spatially non-adjacent lox sites. In some embodiments, one or more removable or activatable elements, or partial / full-length target gene fragments, may be included between the two lox sites to achieve conditional expression control of the target gene. In some embodiments, the gene expression regulatory cassette may include a promoter. In some embodiments, the gene expression regulatory cassette may include a polyadenylated tail. In some embodiments, the gene expression regulatory cassette may, from the 5' end to the 3' end, sequentially include: a promoter, a first lox site, a termination element, a second lox site, the target gene, and a polyadenylated tail.
[0113] In this invention, the term "gene expression regulation system" refers to any form of molecular system, module combination, or engineered device capable of regulating the expression level, expression timing, spatial distribution, or activity of expression products of a target gene in an intracellular or in vitro environment. The gene expression regulation system can achieve upregulation, downregulation, temporal control, or conditional activation / shutdown of gene expression by influencing processes such as transcription, translation, splicing, mRNA stability, post-translational protein modification, protein localization, or degradation. The system may include one or more of the following regulatory modules: a genome-level regulatory module, which can achieve controlled activation or silencing of downstream gene expression by regulating recombinase activity to delete or replace specific sequences (such as termination elements) in the genome; a transcriptional-level regulatory module composed of promoters, enhancers, silencers, operons, and transcription factor binding sites; an RNA-level regulatory module composed of ribozymes, tunable RNA structures, and miRNA / siRNA / shRNA expression cassettes; a protein-level regulatory module composed of protein switches, conditional splicing / activating enzymes, and controlled degradation systems; and inducible regulatory elements including photosensitizers, thermosensitive elements, and small molecule inducible elements.
[0114] In this invention, the term "termination element" refers to a nucleic acid sequence capable of terminating transcription and / or translation during gene expression, and its functions include, but are not limited to, transcription termination, translation repression, mRNA stability regulation, or gene expression regulation. The termination element described in this invention may be derived from wild-type genome sequences, optimized mutant versions, artificially synthesized elements, or genetically engineered functional equivalents, as long as they possess the function of terminating transcription and / or translation. In some embodiments, the termination element may comprise a transcription termination sequence, a translation repression sequence, or a polyadenylated sequence. In some embodiments, the polyadenylated sequence may be SV40polyA or rbGlob polyA, etc. In some embodiments, the termination element has unidirectional lox sites on both sides of it, either adjacent or spaced apart. In some embodiments, the termination element comprises the sequence shown in SEQ ID NO:26.
[0115] In this invention, the term "translation repressor sequence" refers to a nucleotide sequence element capable of inhibiting or reducing the translation efficiency of a target nucleic acid sequence. This sequence can negatively regulate the protein translation process by affecting processes such as ribosome binding, initiation, elongation, or mRNA stability. The translation repressor sequence includes, but is not limited to: GC-rich stem-loop structures forming secondary structures with the translation initiation site, ribosome binding site masking sequences, uORFs (upstream open reading frames), repressive variants of internal ribosome entry sites (IRES), RNA-binding protein recognition sites (such as ARE and GAIT elements), antisense binding regions, and cis-acting elements regulating miRNA or siRNA-mediated silencing. This sequence can exist naturally in the genome of an organism or be obtained through artificial design and optimized synthesis; its function can be reversible, conditionally responsive, or time / tissue-specific.
[0116] In this invention, the term "pluripotent stem cell" refers to a stem cell capable of differentiating into multiple tissue or organ-derived cell types, which can derive various cell lines from germ layers. The pluripotent stem cells described in this invention include, but are not limited to, naturally occurring pluripotent stem cells, gene-edited or chemically induced pluripotent stem cells, cultured and optimized stable cell lines, and artificially designed variants with the same or similar pluripotency characteristics. The types of pluripotent stem cells include, but are not limited to, embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), pluripotent stem cell-like cells (PLSCs), and extended pluripotent stem cells (EPSCs).
[0117] In this invention, the term "adult stem cell" refers to a specific type of stem cell present in a specific tissue or organ, possessing self-renewal capacity and the ability to differentiate into one or more functional cells within that tissue or organ. The adult stem cells described in this invention include naturally occurring, isolated and expanded, in vitro cultured, genetically modified, induced differentiated, and artificially optimized variants, as well as adult stem cells whose function is enhanced through specific stimuli (such as growth factors, gene editing, chemical induction, or exogenous matrix modification). The types of adult stem cells include, but are not limited to, hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), neural stem cells (NSCs), epidermal stem cells (EpSCs), and pancreatic stem cells (PSCs).
[0118] Invention Details
[0119] Fusion protein
[0120] On the one hand, the present invention provides a fusion protein that may comprise an N-terminal fragment of a recombinase, an enzyme cleavage site, a protease, and a C-terminal fragment of a recombinase.
[0121] The N-terminal fragment, cleavage site, protease, and C-terminal fragment of the recombinase in the fusion protein may have different arrangements. In some embodiments, the fusion protein from N-terminus to C-terminus may include the N-terminal fragment of the recombinase, cleavage site, protease, and C-terminal fragment of the recombinase; in some embodiments, the fusion protein from N-terminus to C-terminus may include the N-terminal fragment of the recombinase, protease, cleavage site, and C-terminal fragment of the recombinase; in some embodiments, the fusion protein from N-terminus to C-terminus may include the N-terminal fragment of the recombinase, cleavage site, protease, cleavage site, and C-terminal fragment of the recombinase.
[0122] In some embodiments, the recombinase may be selected from one or more recombinases grouped together with the group consisting of Cre recombinase, Flp recombinase, and Dre recombinase. In some embodiments, the recombinase may be Cre recombinase.
[0123] In some embodiments, the cleavage sites of the N-terminal and C-terminal fragments of the recombinase may be located in the loop-linking region of the Cre enzyme. In some embodiments, the loop-linking region may have regular secondary structures on both sides, which may be independently selected from α-helices, β-sheets, etc. In some embodiments, the loop-linking region may have functionally identical or different domains on both sides.
[0124] In some embodiments, the Cre recombinase may comprise the amino acid sequence shown in SEQ ID NO:22.
[0125] In some embodiments, the splitting sites of the N-terminal and C-terminal fragments of the recombinase can be between amino acid residues at positions 59 and 60, 104 and 106, 155 and 156, 180 and 196, 232 and 233, or 244 and 245, starting from the N-terminus. In some embodiments, the splitting sites of the N-terminal and C-terminal fragments of the recombinase can be: between amino acid residues at positions 104 and 105, 105 and 106, 180 and 181, 181 and 182, 182 and 183, 183 and 184, 184 and 185, 185 and 186, 186 and 187, 187 and 188, 188 and 189, 189 and 190, 190 and 191, 191 and 192, 192 and 193, 193 and 194, 194 and 195, and 195 and 196 from the N-terminus.
[0126] In some embodiments, the protease may be a viral protease that can be used for protein cleavage or degradation.
[0127] In some embodiments, the protease may be selected from one or more proteases from the group consisting of NS3 protease, TEV protease, and 3C / 3CL protease.
[0128] In some embodiments, the protease may be an NS3 protease. In some embodiments, the NS3 protease sequence may comprise isolates of HCV derived from HCV NS3, including any genotype (e.g., genotypes 1-7) or subtype. "Derived from HCV NS3" means that the protease is a serine protease domain of HCV NS3 or a proteolytically active variant thereof capable of cleaving the serine protease domain of HCV NS3 at a cleavage site. In some embodiments, the NS3 may be a truncated form comprising a serine protease domain. In some embodiments, the NS3 protease may comprise a cofactor polypeptide that has the function of activating protease hydrolysis activity, such as a cofactor polypeptide derived from HCV nonstructural protein 4A (NS4A), for example, activating the NS4A region. In some embodiments, the cofactor polypeptide may be located at the N-terminus, C-terminus, or both of the N-terminus and C-terminus of the full-length NS3 protease sequence, i.e., different fragments of the cofactor polypeptide are located at the N-terminus and C-terminus of the NS3 protease, respectively.
[0129] In some embodiments, the NS3 protease may comprise the amino acid sequence shown in SEQ ID NO:23.
[0130] In some embodiments, any two adjacent fragments of the recombinase N-terminal fragment, the restriction site, the protease, and the recombinase C-terminal fragment can be directly linked.
[0131] In some embodiments, any two adjacent fragments of the recombinase N-terminal fragment, the restriction site, the protease, and the recombinase C-terminal fragment may be connected by one or more linkers.
[0132] In some embodiments, the recombinant protein from the N-terminus to the C-terminus may include: an N-terminal fragment of a recombinase, a linker, a restriction enzyme site, a protease, a linker, and a C-terminal fragment of the recombinase. In some embodiments, the recombinant protein from the N-terminus to the C-terminus may include: an N-terminal fragment of a recombinase, a linker, a protease, a linker, a restriction enzyme site, a linker, and a C-terminal fragment of the recombinase. In some embodiments, the recombinant protein from the N-terminus to the C-terminus may include: an N-terminal fragment of a recombinase, a linker, a restriction enzyme site, a linker, a protease, a linker, a restriction enzyme site, a linker, and a C-terminal fragment of the recombinase.
[0133] In some embodiments, the linker can be a flexible linker composed of repeating small, neutral, hydrophilic amino acids (such as glycine and serine) to provide high degrees of freedom and low structural constraints. In some embodiments, the linker can be GGGGS (SEQ ID NO:25), GGSGGS (SEQ ID NO:24), or (GGGGS). n Or (GGSGGS) n , where n is a positive integer, for example, n can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. In some embodiments, the linker may contain the amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:25.
[0134] In some embodiments, the fusion protein may comprise the amino acid sequence shown in SEQ ID NO:1 or SEQ ID NO:3.
[0135] In some embodiments, the activity of the protease can be inhibited by a protease inhibitor to regulate the activity of the fusion protein. The protease inhibitor is cell-permeable and non-toxic to the cells or individuals it comes into contact with.
[0136] In some embodiments, the protease inhibitor may be an NS3 protease inhibitor, which may be selected from one or more of the following groups of inhibitors: Grazoprevir (GZV), Asunaprevir (ASV), Glecaprevir (GLE), Daclatasvir (DCV), Telaprevir (TPV), Danoprevir (DAV), Vaniprevir (VAV), Ciluprevir (BILN 2061), Simeprevir (SMV), Boceprevir (BOC), Sovaprevir (SOV), and Paritaprevir (PTV).
[0137] In some embodiments, the NS3 protease inhibitor may be an ASV, also known as BMS-650032. The ASV includes not only compounds with identical chemical structures, but also pharmaceutically acceptable salts, esters, hydrates, solvates, prodrug forms, isomers (including but not limited to enantiomers, diastereomers, and cis-trans isomers), and derivatives or functionally equivalent compounds obtained by modifying the parent structure without affecting its essential function as an NS3 protease inhibitor.
[0138] polypeptide
[0139] On the other hand, the present invention provides a polypeptide comprising the aforementioned fusion protein. The polypeptide comprises variants or homologs having the same or similar functions. For example, the amino acid sequence of the polypeptide also encompasses variants thereof, including variant sequences in which one or more amino acids have been substituted, deleted, and / or added. Examples include 1-30, 1-20, or 1-10 amino acids, or, for example, 1, 2, 3, 4, 5, 6, 7, 8, or 9 amino acid substitutions, deletions, and / or insertions; homologs are also included, which can be amino acid sequences having at least about 80% (e.g., having at least about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or higher) sequence homology to the amino acid sequence.
[0140] Nucleic acid molecules, vectors
[0141] On the other hand, the present invention provides one or more isolated nucleic acid molecules that can encode the fusion protein or the polypeptide. In some embodiments, the nucleic acid molecule may comprise nucleotides, deoxynucleotides, and / or ribonucleotides of any length in isolated or purified form. In some embodiments, these include (i) in vitro amplification, produced by polymerase chain reaction (PCR) amplification, (ii) production by clonal recombination, (iii) purification, separated by enzyme digestion and gel electrophoresis fractionation in some embodiments, or (iv) synthesis, produced by chemical synthesis in some embodiments. In some embodiments, the isolated nucleic acid may be a nucleic acid molecule prepared using recombinant DNA technology.
[0142] When referring to nucleic acid or nucleotide sequences, it should also be understood to include at least nucleic acid variants or homologs that have the same or similar function as the protein or polypeptide encoded by that nucleic acid sequence. For example, when referring to a "nucleic acid sequence," the nucleic acid sequence also includes its variants, which include variant sequences obtained by codon optimization, point mutation, insertion, deletion, substitution, etc. The nucleic acid sequence also includes its homologs, which can be nucleic acid sequences that have at least about 80% (e.g., at least about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or higher) sequence homology with the nucleic acid sequence.
[0143] On the other hand, the present invention also provides one or more carriers that may contain the isolated nucleic acid molecules.
[0144] The vector can transform, transduce, or transfect host cells, causing the genetic material elements it carries to be expressed within the host cells. In some embodiments, the vector may include a promoter, transcript, enhancer, replicon, selection element, and reporter gene. In some embodiments, the vector may include components that facilitate cell entry. In some embodiments, the vector may include a promoter. In some embodiments, the promoter may be a constitutive promoter.
[0145] The vector may comprise, for example, plasmids, granules, viruses, bacteriophages, or other vectors commonly used in, for example, genetic engineering. In some embodiments, the vector may be an expression vector. In some embodiments, the vector is a transposon vector, which may include mobile transposon elements and auxiliary transposase expression units to transfer and integrate genes into the host genome. In some embodiments, the transposon may be a delivery system built based on the PiggyBac (PB) transposon system. In some embodiments, the vector may be a CRISPR / Cas12b gene editing vector targeting a specific gene site.
[0146] Gene expression regulation system
[0147] On the other hand, the present invention provides a gene expression regulation system, which may include:
[0148] a) the fusion protein, the polypeptide, the nucleic acid molecule, or the vector described herein;
[0149] b) A gene expression regulatory cassette, comprising nucleic acid sequences encoding a target gene, a first lox site, and a second lox site, wherein the first lox site and the second lox site are oriented in the same direction and are not adjacent.
[0150] The gene expression regulation system can regulate the expression level of the target gene.
[0151] In some embodiments, the expression regulation system comprises: a) the nucleic acid molecule or the vector; and b) a gene expression regulation cassette. In some embodiments, portions a) and b) may be in the same vector or located in different vectors. In some embodiments, the expression regulation system may be integrated into the host cell genome or exist in a non-integrated form.
[0152] In some embodiments, the expression regulation system includes: a) the fusion protein or the polypeptide; and b) a gene expression regulation cassette. In some embodiments, the a) partial fusion protein or polypeptide can recognize a first lox site and a second lox site in the b) partial gene expression regulation cassette to achieve expression regulation of the target gene. In some embodiments, the expression regulation system can be integrated into the host cell genome or exist in a non-integrated form. In some embodiments, the a) partial fusion protein or polypeptide can be obtained by transferring the nucleic acid sequence encoding the fusion protein or polypeptide to enable cell autonomous expression, or by directly delivering a pre-synthesized fusion protein or polypeptide to the cell.
[0153] To regulate the expression of a target gene, the expression refers to the process by which a target gene or nucleic acid sequence that was not previously expressed or expressed at a very low level produces detectable RNA and / or protein products in cells after being acted upon by exogenous regulatory means. In some embodiments, a termination element may be included between the first lox site and the second lox site. The termination element may include a transcription termination sequence, a polyadenylated sequence, and / or a translation repressor sequence, and different copy numbers of the above sequences, wherein the copy number is a non-zero positive integer. For example, in some embodiments, the copy number may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. In some embodiments, the gene expression regulation cassette may further include a promoter, and the gene expression regulation system from the 5' end to the 3' end may include: a promoter, a first lox site, a termination element, a second lox site, and a target gene. In some embodiments, the transcription termination sequence is SEQ ID NO:26. In some embodiments, the nucleic acid sequences of the first lox site, the termination element, and the second lox site from the 5' end to the 3' end in the gene expression regulation cassette include the sequence shown in SEQ ID NO:10.
[0154] To achieve the silencing of a target gene, silencing refers to a state in which the target gene or nucleic acid sequence is suppressed or expressed at extremely low levels, making it undetectable in cells. This state can be established, maintained, or deactivated through exogenous regulatory means. In some embodiments, the first lox site and the second lox site contain a portion or the full-length coding sequence of the target gene. In some embodiments, the portion or full-length coding sequence of the target gene contains the exon coding sequence of the target gene. In some embodiments, the first lox site and the second lox site may be the 5' end and 3' end of the target gene, respectively, and the full-length coding sequence of the target gene is contained between the two lox sites. In some embodiments, the first lox site and the second lox site may be located in different intron coding sequence regions of the target gene, and one or more exon coding sequences of the target gene are contained between the two lox sites. In some embodiments, the exon sequence encodes a key active site of the protein expressed by the target gene.
[0155] In some embodiments, the first lox site and the second lox site may be independently selected from the wild-type loxP site and the mutated lox site. In some embodiments, the mutated lox site may be selected from one or more sites from the group consisting of: LoxN site, Lox2272 site, Lox511 site, Lox5171 site, LoxM2 site, Lox66 site, and Lox71 site.
[0156] In some embodiments, the gene expression regulation system may further include a reporter gene, which indicates whether parts a) and b) of the gene expression regulation system exist independently in a cell or system, or whether they are jointly introduced into the same cell or system. In some embodiments, parts a) and b) may further include different reporter genes. In some embodiments, the reporter gene does not share the same promoter as the target gene, i.e., the reporter gene can be expressed independently. In some embodiments, the reporter gene may be a fluorescent protein encoding gene, an resistance gene, an enzyme gene, a membrane localization protein gene, etc. In some embodiments, the reporter gene may encode green fluorescent protein (GFP), blue fluorescent protein (BFP), and / or red fluorescent protein (e.g., mCherry). In some embodiments, the reporter gene may encode a gene-edited CD19 molecule (tCD19) and / or a gene-edited epidermal growth factor receptor (tEGFR). In some embodiments, part a) of the gene expression regulation system includes a reporter gene encoding mCherry, and part b) includes a reporter gene encoding BFP. In some embodiments, the gene expression regulation system includes a portion a) containing a reporter gene encoding tCD19 and a portion b) containing a reporter gene encoding tEGFR.
[0157] cell
[0158] On the other hand, the present invention provides a cell that may contain the fusion protein, the polypeptide, the isolated nucleic acid molecule, the vector, or the gene expression regulation system.
[0159] In some embodiments, the cells include pluripotent stem cells, adult stem cells, immune cells, nerve cells, and / or endocrine cells.
[0160] In some embodiments, the pluripotent stem cells are selected from one or more cells from the group consisting of embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), pluripotent stem cells similar to pluripotent stem cells (PLSCs), and extended pluripotent stem cells (EPSCs).
[0161] In some embodiments, the adult stem cells are selected from one or more cells from the group consisting of hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), neural stem cells (NSCs), epidermal stem cells (EpSCs), and pancreatic stem cells (PSCs).
[0162] In some embodiments, the immune cells are selected from one or more cells from the group consisting of T lymphocytes, macrophages, NK cells, and NKT cells.
[0163] In some embodiments, the endocrine cells are pancreatic β cells.
[0164] In some embodiments, the nerve cells are dopamine nerve cells.
[0165] method
[0166] On the other hand, the present invention provides a method for regulating a target gene, the method comprising: adding a protease inhibitor to the cell to regulate the activity of the fusion protein, thereby regulating the expression or silencing of the target gene. The protease inhibitor is cell-permeable and non-toxic to the cells or individuals it contacts.
[0167] In some embodiments, the method may add the protease inhibitor to the cells multiple times, for example, once, twice, three times, four times, five times, six times, seven times, eight times, nine times, or ten times.
[0168] In some embodiments, the method may involve adding protease inhibitors at specific stages or time points in the cells. These specific stages or time points may be the stages or time points where the target gene needs to be expressed or silenced; for example, for pluripotent or adult stem cells, adding protease inhibitors during their differentiation into terminal cells to express or silence the target gene. In some embodiments, the multiple additions of protease inhibitors may occur at different stages or time points. Drug induction at specific stages of human pluripotent stem cell differentiation into terminal cells not only helps to stably produce large quantities of target-derived cells, thereby reducing costs, but also ensures the integrity or enhancement of the function of human pluripotent stem cell-derived cells, thereby improving the effectiveness of the therapy. Specific problems addressed include, but are not limited to: 1. Maintaining the pluripotency state of human pluripotent stem cells after editing; 2. Reducing the impact of target gene editing on the differentiation process of human pluripotent stem cells into derived cells; 3. Efficiently and stably expressing the target gene; 4. Achieving a wider range and more versatile gene loading pathway.
[0169] In some embodiments, the protease inhibitor is an NS3 protease inhibitor selected from one or more of the following groups of inhibitors: Grazoprevir (GZV), Asunaprevir (ASV), Glecaprevir (GLE), Daclatasvir (DCV), Telaprevir (TPV), Danoprevir (DAV), Vaniprevir (VAV), Ciluprevir (BILN 2061), Simeprevir (SMV), Boceprevir (BOC), Sovaprevir (SOV), and Paritaprevir (PTV).
[0170] In some embodiments, the NS3 protease inhibitor may be an ASV, also known as BMS-650032. The ASV includes not only compounds with identical chemical structures, but also pharmaceutically acceptable salts, esters, hydrates, solvates, prodrug forms, isomers (including but not limited to enantiomers, diastereomers, and cis-trans isomers), and derivatives or functionally equivalent compounds obtained by modifying the parent structure without affecting its essential function as an NS3 protease inhibitor.
[0171] In some embodiments, the method is an in vitro or ex vivo method.
[0172] use
[0173] On the other hand, the present invention provides the use of the fusion protein, the polypeptide, the nucleic acid, the vector, the gene expression regulation system, the cell, and the method thereof in the preparation of a drug for the prevention and / or treatment of a disease.
[0174] In some embodiments, the diseases include, but are not limited to, hematologic malignancies, solid tumors, autoimmune diseases, endocrine and metabolic diseases, nervous system diseases, respiratory diseases, inflammatory diseases, and infectious diseases.
[0175] In some embodiments, the autoimmune diseases include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; the endocrine diseases include, but are not limited to, diabetes; the neurological diseases include, but are not limited to, Parkinson's disease and Alzheimer's disease; the respiratory diseases include, but are not limited to, pneumonia and pulmonary fibrosis; and the inflammatory diseases include osteoarthritis.
[0176] The embodiments described below are not intended to be limited by any theory, but are merely for illustrating the fusion protein, preparation method and use of this application, and are not intended to limit the scope of the invention.
[0177] Example
[0178] Example 1: Analysis of the effect of ASV drug treatment on cell proliferation
[0179] Embryonic stem cells (ES cells) are cultured to a suitable density (typically 70-80% confluence), digested into single cells using TrypLE or other appropriate digestion solutions, centrifuged (e.g., 1000 rpm, 5 min) and resuspended in fresh culture medium, stained with AO / PI staining solution, and viable cell counted using an automated cell counter to record the viable cell concentration.
[0180] Aspirate an equal volume of cells (e.g., 1 x 10⁻⁶) from the ES cell suspension. 5 Cells (1 cell / well) were added to eight pre-coated 12-well plates containing vitronectin (VTN). Four wells were treated with 1 μM ASV, while the remaining four wells served as a control group without any drug. Cells were cultured at 37°C in a 5% CO2 incubator, with Day 0 defined as the day of passage. Cells were collected at Day 1, Day 2, Day 3, and Day 4, and viable cell counts were performed using AO / PI staining. The number of viable cells at each time point was recorded, and cell proliferation curves were plotted to compare cell proliferation between the ASV-treated group and the control group.
[0181] The results showed that the cell proliferation curves of the ASV-treated group and the control group were basically the same, indicating that ASV at a concentration of 1 μM had no significant effect on the proliferation of ES cells, and that ASV at this concentration neither inhibited nor promoted the proliferation of ES cells. (Figure 1)
[0182] Example 2: Gene Editing Strategy of GFP Gene Expression Control System 1
[0183] Gene expression frames for Part 1 and Part 2 were constructed based on the sequence information in the sequence listing. The GFP gene expression control system 1 consists of two parts. The first part includes a CAG promoter-Cre structure 1 split gene expression box-CAG promoter-mCherry-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5; the Cre structure 1 split nucleic acid sequence is shown in SEQ ID NO:2, which contains a nucleic acid sequence encoding the NS3 protease with the amino acid sequence SEQ ID NO:23; the mCherry-Tag nucleic acid sequence is shown in SEQ ID NO:20), and the Cre split site of the Cre structure 1 split is located between position 59 and position 60 of SEQ ID NO:22; the second part includes a CAG promoter-Loxp-Stop-Loxp-GFP gene expression box-CAG promoter-BFP-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5, the Loxp-Stop-Loxp nucleic acid sequence is shown in SEQ ID NO:10, the GFP nucleic acid sequence is shown in SEQ ID NO:12, and the BFP-Tag nucleic acid sequence is shown in SEQ ID NO:7) (Figure 22). All sequences were synthesized at Genscript Biotech Ltd., and are shown in the sequence listing.
[0184] Using the laboratory Piggybac with ampicillin resistance backbone (SEQ ID NO:21) as a vector, PCR was performed on the CAG promoter-Cre structure 1 gene expression cassette split using primers F1 (SEQ ID NO:27) and R1 (SEQ ID NO:28), and on the CAG promoter-mCherry-Tag using primers F2 (SEQ ID NO:29) and R2 (SEQ ID NO:30). The two PCR products were then infused with the linearized Piggybac with ampicillin resistance backbone vector to obtain the recombinant plasmid CAG promoter-Cre structure 1 gene expression cassette split-CAG promoter-mCherry-Tag. PCR was performed on the CAG promoter-Loxp-Stop-Loxp-GFP gene expression cassette using primers F3 (SEQ ID NO:31) and R3 (SEQ ID NO:32), and on the CAG promoter-BFP-Tag using primers F4 (SEQ ID NO:33) and R4 (SEQ ID NO:34). The two PCR products were then infused with a linearized Piggybac vector containing ampicillin resistance, resulting in a recombinant plasmid named CAG promoter-Loxp-Stop-Loxp-GFP gene expression cassette-CAG promoter-BFP-Tag. The two elements were then integrated into the ES genome using the Piggybac integration method.
[0185] Example 3: Gene Editing Strategy of GFP Gene Expression Control System 2
[0186] Gene expression frames for Part 1 and Part 2 were constructed based on the sequence information in the sequence listing. The GFP gene expression control system 2 consists of two parts. The first part includes a CAG promoter-Cre structure 2 split gene expression cassette-CAG promoter-mCherry-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5; the Cre structure 2 split nucleic acid sequence is shown in SEQ ID NO:4, which contains a nucleic acid sequence encoding the NS3 protease with the amino acid sequence SEQ ID NO:23; the mCherry-Tag nucleic acid sequence is shown in SEQ ID NO:20), and the Cre split site of the Cre structure 2 split is located between positions 244 and 245 of SEQ ID NO:22. The second part includes a CAG promoter-Loxp-Stop-Loxp-GFP gene expression cassette-CAG promoter-BFP-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5, the Loxp-Stop-Loxp nucleic acid sequence is shown in SEQ ID NO:10, the GFP nucleic acid sequence is shown in SEQ ID NO:12, and the BFP-Tag nucleic acid sequence is shown in SEQ ID NO:20). (See NO:7) (Figure 22). All sequences were synthesized at Genscript Biotech Ltd., as shown in the sequence listing.
[0187] Using the laboratory Piggybac with ampicillin resistance backbone (SEQ ID NO:21) as a vector, PCR was performed on the CAG promoter-Cre structure 2 gene expression cassette split using primers F1 (SEQ ID NO:27) and R1 (SEQ ID NO:28), and on the CAG promoter-mCherry-Tag using primers F2 (SEQ ID NO:29) and R2 (SEQ ID NO:30). The two PCR products were then infused with the linearized Piggybac with ampicillin resistance backbone vector to obtain the recombinant plasmid CAG promoter-Cre structure 2 gene expression cassette split-CAG promoter-mCherry-Tag. PCR was performed on the CAG promoter-Loxp-Stop-Loxp-GFP gene expression cassette using primers F3 (SEQ ID NO:31) and R3 (SEQ ID NO:32), and on the CAG promoter-BFP-Tag using primers F4 (SEQ ID NO:33) and R4 (SEQ ID NO:34). The two PCR products were then infused with a linearized Piggybac vector containing ampicillin resistance, resulting in a recombinant plasmid named CAG promoter-Loxp-Stop-Loxp-GFP gene expression cassette-CAG promoter-BFP-Tag. The two elements were then integrated into the ES genome using the Piggybac integration method.
[0188] Example 4: Gene Editing Strategy of TGFBRc Gene Expression Control System 2
[0189] The TGFBRc gene expression control system 2 consists of two parts. The first part includes a CAG promoter-Cre structure 2 splitting gene expression cassette-CAG promoter-tCD19-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5; the Cre structure 2 splitting nucleic acid sequence is shown in SEQ ID NO:4, which contains a nucleic acid sequence encoding the NS3 protease with the amino acid sequence SEQ ID NO:23; the tCD19-Tag nucleic acid sequence is shown in SEQ ID NO:9), and the Cre splitting site of the Cre structure 2 splitting is located between positions 244 and 245 of SEQ ID NO:22. The second part includes a CAG promoter-Loxp-Stop-Loxp-TGFBRc gene expression cassette-CAG promoter-tEGFR-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5, the Loxp-Stop-Loxp nucleic acid sequence is shown in SEQ ID NO:10, and the TGFBRc nucleic acid sequence is shown in SEQ ID NO:4). As shown in NO:18, the tEGFR-Tag nucleic acid sequence is shown in SEQ ID NO:14 (Figure 24). All sequences were synthesized by Genscript Biotech Ltd., as shown in the sequence listing.
[0190] Using the laboratory Piggybac vector with ampicillin resistance (SEQ ID NO:21) as a vector, PCR was performed on the CAG promoter-Cre structure 2 gene expression cassette split using primers F1 (SEQ ID NO:27) and R1 (SEQ ID NO:28), and on the CAG promoter-tCD19-Tag using primers F2 (SEQ ID NO:29) and R2 (SEQ ID NO:30). The two PCR products were then infused with the linearized Piggybac vector with ampicillin resistance to obtain the recombinant plasmid CAG promoter-Cre structure 2 gene expression cassette split-CAG promoter-tCD19-Tag. PCR was performed on the CAG promoter-Loxp-Stop-Loxp-TGFBRc gene expression cassette using primers F3 (SEQ ID NO:31) and R3 (SEQ ID NO:32), and on the CAG promoter-tEGFR-Tag using primers F5 (SEQ ID NO:35) and R5 (SEQ ID NO:28). The two PCR products were then infused with a linearized Piggybac vector containing ampicillin resistance, resulting in a recombinant plasmid of CAG promoter-Loxp-Stop-Loxp-TGFBRc gene expression cassette-CAG promoter-tEGFR-Tag. The two elements were then integrated into the ES genome using the Piggybac integration method.
[0191] Example 5: Gene Editing Strategy of BCMA.CAR Gene Expression Control System 2
[0192] The BCMA.CAR gene expression control system 2 consists of two parts. The first part includes a CAG promoter-Cre structure 2 splitting gene expression cassette-CAG promoter-tCD19-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5; the Cre structure 2 splitting nucleic acid sequence is shown in SEQ ID NO:4, which contains a nucleic acid sequence encoding the NS3 protease with the amino acid sequence SEQ ID NO:23; the tCD19-Tag nucleic acid sequence is shown in SEQ ID NO:9), and the Cre splitting site of the Cre structure 2 splitting is located between positions 244 and 245 of SEQ ID NO:22; the second part includes a CAG promoter-Loxp-Stop-Loxp-BCMA.CAR gene expression cassette-CAG promoter-tEGFR-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5, the Loxp-Stop-Loxp nucleic acid sequence is shown in SEQ ID NO:10, and the BCMA.CAR nucleic acid sequence is shown in SEQ ID NO:4). As shown in NO:16, the tEGFR-Tag nucleic acid sequence is shown in SEQ ID NO:14 (Figure 23). All sequences were synthesized at Genscript Biotech Ltd., as shown in the sequence listing.
[0193] Using the laboratory Piggybac vector with ampicillin resistance (SEQ ID NO:21) as a vector, PCR was performed on the CAG promoter-Cre structure 2 gene expression cassette split using primers F1 (SEQ ID NO:27) and R1 (SEQ ID NO:28), and on the CAG promoter-tCD19-Tag using primers F2 (SEQ ID NO:29) and R2 (SEQ ID NO:30). The two PCR products were then infused with the linearized Piggybac vector with ampicillin resistance to obtain the recombinant plasmid CAG promoter-Cre structure 2 gene expression cassette split-CAG promoter-tCD19-Tag. PCR was performed on the CAG promoter-Loxp-Stop-Loxp-BCMA.CAR gene expression cassette using primers F3 (SEQ ID NO:31) and R3 (SEQ ID NO:32), and on the CAG promoter-tEGFR-Tag using primers F5 (SEQ ID NO:35) and R5 (SEQ ID NO:28). The two PCR products were then infused with a linearized Piggybac vector containing ampicillin resistance, resulting in a recombinant plasmid named CAG promoter-Loxp-Stop-Loxp-BCMA.CAR gene expression cassette-CAG promoter-tEGFR-Tag. The two elements were then integrated into the ES genome using the Piggybac integration method.
[0194] Example 6: Construction of a cell line for the GFP gene expression control system 1
[0195] According to the design of the GFP gene expression control system 1, a Piggybac vector containing the following components was constructed: Part 1: CAG promoter-Cre structure 1 split gene expression cassette-CAG promoter-mCherry-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5; the Cre structure 1 split nucleic acid sequence is shown in SEQ ID NO:2, which contains a nucleic acid sequence encoding the NS3 protease with the amino acid sequence SEQ ID NO:23; the mCherry-Tag nucleic acid sequence is shown in SEQ ID NO:20), the Cre split site of the Cre structure 1 split is located between positions 59 and 60 of SEQ ID NO:22; Part 2: CAG promoter-Loxp-Stop-Loxp-GFP gene expression cassette-CAG promoter-BFP-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5, the Loxp-Stop-Loxp nucleic acid sequence is shown in SEQ ID NO:10, the GFP nucleic acid sequence is shown in SEQ ID NO:12, and the BFP-Tag nucleic acid sequence is shown in SEQ ID NO:20). (NO:7 shown). Culture ES cells to a suitable density (usually 70-80% confluence), digest single cells using TrypLE or other suitable digestion solution, centrifuge (e.g., 1000 rpm, 5 min) and resuspend cells in fresh culture medium, stain cells with AO / PI staining solution, count viable cells using an automated cell counter, record viable cell concentration, transfer 1.5e6 cells to a 1.5 mL centrifuge tube, centrifuge again at 100 rpm / 5 min to remove supernatant.
[0196] Add 6 μg of the plasmid (Piggybac enzyme plasmid: Part 1 plasmid: Part 2 plasmid = 1:1:1) to P3 Buffer (82 μL P3 + 18 μL supplement) and mix well (electroporation kit: P3 Primary Cell). Using the X Kit, carefully add the cell mixture to the electroporation cuvette. The electroporation program is CA137. After electroporation, transfer the cells to 6-well plates for culture. After approximately 6 days of culture, sort the cells for mCherry-Tag and BFP-Tag positive cells into 96-well plates. About one week later, passage and amplify the single clones. Once the cell count reaches a certain level, flow cytometry analysis is performed on the expression of mCherry-Tag, BFP-Tag, and the control gene GFP in individual clones.
[0197] In the absence of ASV treatment, all selected monoclonal cells expressed mCherry-Tag and BFP-Tag, but not GFP (Figure 2A). An ES cell line expressing a GFP gene expression control system 1 was successfully constructed. This system stably expressed mCherry-Tag and BFP-Tag without ASV treatment, while inhibiting GFP expression. This system can be used to study gene expression regulation and drug-induced gene expression changes.
[0198] Example 7: Construction of a cell line expressing GFP gene expression control system 2
[0199] According to the design of the GFP gene expression control system 2, a Piggybac vector containing the following components was constructed: Part 1: CAG promoter-Cre structure 2 split gene expression cassette-CAG promoter-mCherry-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5; the Cre structure 2 split nucleic acid sequence is shown in SEQ ID NO:4, which contains a nucleic acid sequence encoding the NS3 protease with the amino acid sequence SEQ ID NO:23; the mCherry-Tag nucleic acid sequence is shown in SEQ ID NO:20), the Cre split site of the Cre structure 2 split is located between positions 244 and 245 of SEQ ID NO:22; Part 2: CAG promoter-Loxp-Stop-Loxp-GFP gene expression cassette-CAG promoter-BFP-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5, the Loxp-Stop-Loxp nucleic acid sequence is shown in SEQ ID NO:10, the GFP nucleic acid sequence is shown in SEQ ID NO:12, and the BFP-Tag nucleic acid sequence is shown in SEQ ID NO:20). (NO:7 shown). Culture ES cells to a suitable density (usually 70-80% confluence), digest single cells using TrypLE or other suitable digestion solution, centrifuge (e.g., 1000 rpm, 5 min) and resuspend cells in fresh culture medium, stain cells with AO / PI staining solution, count viable cells using an automated cell counter, record viable cell concentration, transfer 1.5e6 cells to a 1.5 mL centrifuge tube, centrifuge again at 100 rpm / 5 min to remove supernatant.
[0200] Add 6 μg of the plasmid (Piggybac enzyme plasmid: Part 1 plasmid: Part 2 plasmid = 1:1:1) to P3 Buffer (82 μL P3 + 18 μL supplement) and mix well (electroporation kit: P3 Primary Cell). Using the X Kit, carefully add the cell mixture to the electroporation cuvette. The electroporation program is CA137. After electroporation, transfer the cells to 6-well plates for culture. After approximately 6 days of culture, sort the cells for mCherry-Tag and BFP-Tag positive cells into 96-well plates. About one week later, passage and amplify the single clones. Once the cell count reaches a certain level, flow cytometry analysis is performed on the expression of mCherry-Tag, BFP-Tag, and the control gene GFP in individual clones.
[0201] In the absence of ASV treatment, all selected monoclonal cells expressed mCherry-Tag and BFP-Tag, but not GFP (Figure 2B). An ES cell line expressing the GFP gene expression control system 2 was successfully constructed. This system stably expressed mCherry-Tag and BFP-Tag without ASV treatment, while inhibiting GFP expression. This system can be used to study gene expression regulation and drug-induced gene expression changes.
[0202] Example 8: Construction of a cell line expressing the TGFBRc gene expression control system 2
[0203] According to the design of the TGFBRc gene expression control system 2, a Piggybac vector containing the following components was constructed: Part 1: CAG promoter-Cre structure 2 split gene expression cassette-CAG promoter-tCD19-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5; the Cre structure 2 split nucleic acid sequence is shown in SEQ ID NO:4, which contains a nucleic acid sequence encoding the NS3 protease with the amino acid sequence of SEQ ID NO:23; the tCD19-Tag nucleic acid sequence is shown in SEQ ID NO:9), wherein the Cre split site of the Cre structure 2 split is located between positions 244 and 245 of SEQ ID NO:22; Part 2: CAG promoter-Loxp-Stop-Loxp-TGFBRc gene expression cassette-CAG promoter-tEGFR-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5, the Loxp-Stop-Loxp nucleic acid sequence is shown in SEQ ID NO:10, and the TGFBRc nucleic acid sequence is shown in SEQ ID NO:9). As shown in NO:18, the tEGFR-Tag nucleic acid sequence is shown in SEQ ID NO:14. Culture ES cells to a suitable density (typically 70-80% confluence), perform single-cell digestion using TrypLE or other suitable digestion solutions, centrifuge (e.g., 1000 rpm, 5 min) and resuspend the cells in fresh culture medium, stain the cells with AO / PI staining solution, count the viable cells using an automated cell counter, record the viable cell concentration, transfer 1.5e6 cells to a 1.5 mL centrifuge tube, and centrifuge again at 100 rpm / 5 min to remove the supernatant.
[0204] Add 6 μg of the plasmid (Piggybac enzyme plasmid: Part 1 plasmid: Part 2 plasmid = 1:1:1) to P3 Buffer (82 μl P3 + 18 μl supplement) and mix well (electroporation kit: P3 Primary Cell). Using the X Kit, carefully add the cell mixture to the electroporation cuvette. The electroporation program is CA137. After electroporation, transfer the cells to 6-well plates for culture. After approximately 6 days of culture, sort the cells for tCD19-Tag and tEGFR-Tag positive cells into 96-well plates. About one week later, passage and expand the single clones. Once the cell count reaches a certain level, flow cytometry analysis is performed on the expression of tCD19-Tag, tEGFR-Tag, and the control gene TGFBRc in individual clones.
[0205] In the absence of ASV treatment, all selected monoclonal cells expressed tCD19-Tag and tEGFR-Tag, but not TGFBRc (Figure 5). An ES cell line expressing the TGFBRc gene expression control system 2 was successfully constructed. This system stably expressed tCD19-Tag and tEGFR-Tag without ASV treatment, while inhibiting TGFBRc expression. This system can be used to study gene expression regulation and drug-induced gene expression changes.
[0206] Example 9: Construction of a cell line expressing the BCMA.CAR gene expression control system 2
[0207] According to the design of the BCMA.CAR gene expression control system 2, a Piggybac vector containing the following elements was constructed: Part 1: CAG promoter-Cre structure 2 split gene expression cassette-CAG promoter-tCD19-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5, the Cre structure 2 split nucleic acid sequence is shown in SEQ ID NO:4, and the tCD19-Tag nucleic acid sequence is shown in SEQ ID NO:9), the Cre split site of the Cre structure 2 split is located between positions 244 and 245 of SEQ ID NO:22; Part 2: CAG promoter-Loxp-Stop-Loxp-BCMA.CAR gene expression cassette-CAG promoter-tEGFR-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5, the Loxp-Stop-Loxp nucleic acid sequence is shown in SEQ ID NO:10, the BCMA.CAR nucleic acid sequence is shown in SEQ ID NO:16, and the tEGFR-Tag nucleic acid sequence is shown in SEQ ID NO:14). Culture ES cells to a suitable density (usually 70-80% confluence), digest single cells using TrypLE or other appropriate digestion solutions, centrifuge (e.g., 1000 rpm, 5 min) and resuspend the cells in fresh culture medium, stain the cells with AO / PI staining solution, count the viable cells using an automated cell counter, record the viable cell concentration, transfer 1.5e6 cells to a 1.5 mL centrifuge tube, centrifuge again at 100 rpm / 5 min to remove the supernatant.
[0208] Add 6 μg of the plasmid (Piggybac enzyme plasmid: Part 1 plasmid: Part 2 plasmid = 1:1:1) to P3 Buffer (82 μl P3 + 18 μl supplement) and mix well (electroporation kit: P3 Primary Cell). Using the X Kit, carefully add the cell mixture to the electroporation cuvette. Electroporation is performed using the CA137 program. After electroporation, transfer the cells to 6-well plates for culture. After approximately 6 days of culture, tCD19-Tag and tEGFR-Tag positive cells are sorted into 96-well plates. After about one week, single clones are passaged and expanded. Once a sufficient number of cells have been produced, flow cytometry analysis is performed on the expression of tCD19-Tag, tEGFR-Tag, and the control gene BCMA.CAR in individual clones.
[0209] In the absence of ASV treatment, all selected monoclonal cells expressed tCD19-Tag and tEGFR-Tag, but not BCMA.CAR (Figure 7). An ES cell line expressing the BCMA.CAR gene expression control system 2 was successfully constructed. This system stably expressed tCD19-Tag and tEGFR-Tag without ASV treatment, while inhibiting BCMA.CAR expression. This system can be used to study gene expression regulation and drug-induced gene expression changes.
[0210] Example 10: The cell line expressing the GFP gene expression control system 1 was used to perform an induction test of GFP gene expression on an ES cell line.
[0211] First, monoclonal cells were selected from the cell line expressing the GFP gene expression control system 1 and expanded to ensure good cell condition and a viable cell ratio greater than 90%. Then, the expanded monoclonal cells were seeded into 24-well plates at a density of 5 × 10^4 cells / well, with 2 mL of complete culture medium added to each well to ensure uniform cell distribution. The day of seeding was designated D0. The 24-well plates were divided into two groups: one group was treated with ASV drug, with a final concentration of 1 μM ASV drug added to the culture medium at D0; the other group was a control group, without ASV drug. Both groups of cells were cultured in an incubator at 37°C and 5% CO2.
[0212] Starting from day 0, cells were collected at different time points, and GFP expression was detected using flow cytometry. After day 7, ASV treatment was stopped, cells were cultured again, and GFP expression was continuously monitored to observe the maintenance of expression after drug withdrawal. Before each assay, cells were washed with PBS, resuspended in flow cytometry buffer, and the proportion of GFP-positive cells was detected and recorded.
[0213] The experimental results showed that the GFP expression rate in the ASV drug treatment group exceeded 80% on day 4 and further increased to over 90% on day 7, indicating that ASV drugs can efficiently induce GFP gene expression. The GFP expression rate in the control group remained below 1% throughout the experiment, demonstrating that the GFP gene expression control system 1 effectively inhibited GFP expression in the absence of ASV drug treatment.
[0214] After ASV treatment was stopped, the GFP expression rate remained at approximately 90% without a significant decrease, indicating that ASV-induced GFP expression has high stability. Flow cytometry data further confirmed that the proportion of GFP-positive cells in the ASV-treated group was significantly higher than that in the control group, and the induction effect was time-dependent. (Figure 3)
[0215] This experiment successfully verified the highly efficient induction effect of ASV drugs on the GFP gene expression control system 1. ASV drugs significantly increased the GFP expression ratio within a short period (D4) and maintained a high expression level for a longer period (D7 and beyond). This result indicates that the GFP gene expression control system 1 possesses high controllability and stability.
[0216] Example 11: Cell lines expressing GFP gene expression control system 2 were tested for GFP gene expression induction on ES.
[0217] First, monoclonal cells were selected from the cell line expressing the GFP gene expression control system 2 and expanded to ensure good cell condition and a viable cell ratio greater than 90%. Then, the expanded monoclonal cells were seeded into 24-well plates at a density of 5 × 10^4 cells / well, with 2 mL of complete culture medium added to each well to ensure uniform cell distribution. The day of seeding was designated D0. The 24-well plates were divided into two groups: one group was treated with ASV drug, with a final concentration of 1 μM ASV drug added to the culture medium at D0; the other group was a control group, without ASV drug. Both groups of cells were cultured in an incubator at 37°C and 5% CO2.
[0218] Starting from day 0, cells were collected at different time points, and GFP expression was detected using flow cytometry. After day 7, ASV treatment was stopped, cells were cultured again, and GFP expression was detected again to observe the maintenance of expression after drug withdrawal. Before each detection, cells were washed with PBS, resuspended in flow cytometry buffer, and the proportion of GFP-positive cells was recorded.
[0219] The experimental results showed that the GFP expression rate in the ASV drug treatment group exceeded 80% on day 1 and further increased to over 93% on day 2, indicating that ASV drugs can rapidly and efficiently induce GFP gene expression. The GFP expression rate in the control group remained below 1% throughout the experiment, demonstrating that the GFP gene expression control system 2 effectively inhibited GFP expression in the absence of ASV drug treatment.
[0220] At day 2, the GFP expression rate in the ASV-treated group reached over 93%, indicating that the induction effect peaked within a short period. After the ASV treatment was stopped, the GFP expression rate remained at around 98%, without a significant decrease, indicating that ASV-induced GFP expression has extremely high stability. Flow cytometry data further confirmed that the proportion of GFP-positive cells in the ASV-treated group was significantly higher than that in the control group, and the induction effect was characterized by rapid response and high efficiency (Figure 4).
[0221] Further, a DAV drug treatment group was set up, and the above experimental procedure was repeated under the same experimental conditions. The results in Figure 34 show that the trend of GFP expression in the DAV drug treatment group was consistent with that in the ASV treatment group, and no significant difference was observed. Both groups showed that GFP expression increased rapidly after drug treatment and remained at a relatively stable level in the subsequent time.
[0222] This experiment successfully verified the highly efficient induction effect of NS3 protease inhibitors on GFP gene expression control system 2. NS3 protease inhibitors significantly increased the GFP expression ratio within a very short time (D1), and reached a near 100% expression level within a short period (D2 and thereafter). This result indicates that GFP gene expression control system 2 has higher induction efficiency and stability.
[0223] Example 12: The cell line expressing the TGFBRc gene expression control system 2 was used to perform an induction test on an ES cell line to induce TGFBRc gene expression.
[0224] First, monoclonal cells were selected from the cell line expressing the TGFBRc gene expression control system 2 and expanded to ensure good cell condition and a viable cell ratio greater than 90%. Then, the expanded monoclonal cells were seeded into 24-well plates at a density of 5 × 10^4 cells / well, with 2 mL of complete culture medium added to each well to ensure uniform cell distribution. The day of seeding was designated D0. The 24-well plates were divided into two groups: one group was treated with ASV drug, with a final concentration of 1 μM ASV drug added to the culture medium at D0; the other group was a control group, without ASV drug. Both groups of cells were cultured in an incubator at 37°C and 5% CO2.
[0225] Starting from day 0, cells were collected at different time points, and TGFBRc expression was detected using flow cytometry. After day 5, ASV treatment was stopped, cells were cultured again, and TGFBRc expression was continuously monitored to observe the maintenance of expression after drug withdrawal. Before each assay, cells were washed with PBS, resuspended in flow cytometry buffer, and the proportion of TGFBRc-positive cells was detected and recorded.
[0226] The experimental results showed that the TGFBRc expression rate in the ASV drug treatment group exceeded 97% on day 2 and further increased to over 99% on day 4, indicating that ASV drugs can rapidly and efficiently induce TGFBRc gene expression. In the control group, the TGFBRc expression rate remained below 1% throughout the experiment, demonstrating that the TGFBRc gene expression control system 2 effectively inhibited TGFBRc expression in the absence of ASV drug treatment.
[0227] At day 5, the TGFBRc expression rate in the ASV-treated group reached over 99%, indicating that the induction effect peaked rapidly. After ASV treatment was stopped, the TGFBRc expression rate remained at around 98%, without a significant decrease, indicating that ASV-induced TGFBRc expression has extremely high stability. Flow cytometry data further confirmed that the proportion of TGFBRc-positive cells in the ASV-treated group was significantly higher than that in the control group, and the induction effect was characterized by rapid response and high efficiency. (Figure 6)
[0228] Example 13: The cell line expressing the BCMA.CAR gene expression control system 2 was used to test the induction of BCMA.CAR gene expression on an ES cell line.
[0229] First, monoclonal cells were selected from the cell line expressing the BCMA.CAR gene expression control system 2 and expanded to ensure good cell condition and a viable cell ratio greater than 90%. Then, the expanded monoclonal cells were seeded into 24-well plates at a density of 5 × 10^4 cells / well, with 2 mL of complete culture medium added to each well to ensure uniform cell distribution. The day of seeding was designated D0. The 24-well plates were divided into two groups: one group was treated with ASV drug, with a final concentration of 1 μM ASV drug added to the culture medium at D0; the other group was a control group, without ASV drug. Both groups of cells were cultured in an incubator at 37°C and 5% CO2.
[0230] Starting from day 0, cells were collected at different time points, and BCMA.CAR expression was detected by flow cytometry. After day 4, ASV treatment was stopped, cells were cultured again, and BCMA.CAR expression was continuously monitored to observe the maintenance of expression after drug withdrawal. Before each assay, cells were washed with PBS, resuspended in flow cytometry buffer, and the proportion of BCMA.CAR-positive cells was recorded. Monitoring of the untreated group continued until day 5 to compare the effects of drug treatment.
[0231] The experimental results showed that the BCMA.CAR expression rate in the ASV drug treatment group exceeded 91% on day 1 and further increased to over 99% on day 2, indicating that ASV drugs can rapidly and efficiently induce BCMA.CAR gene expression. The BCMA.CAR expression rate in the control group remained below 1% throughout the experiment, demonstrating that the BCMA.CAR gene expression control system 2 effectively inhibited BCMA.CAR expression in the absence of ASV drug treatment.
[0232] At day 4, the BCMA.CAR expression rate in the ASV-treated group reached over 99%, indicating that the induction effect peaked rapidly. After ASV treatment was stopped, the BCMA.CAR expression rate remained relatively stable at around 99%, without a significant decrease, demonstrating the high stability of ASV-induced BCMA.CAR expression. Flow cytometry data further confirmed that the proportion of BCMA.CAR-positive cells in the ASV-treated group was significantly higher than that in the control group, and the induction effect exhibited rapid response and high efficiency. (Figure 8)
[0233] Example 14: The expression of the BCMA.CAR gene expression control system 2 in a cell line was induced during the differentiation of ES cells into NK cells.
[0234] First, monoclonal cells were selected from the cell line expressing the BCMA.CAR gene expression control system 2 and expanded to ensure a sufficient number of cells for subsequent differentiation experiments. Then, following the standard procedure for ES cell to NK cell differentiation, the expanded monoclonal cells were induced to differentiate into NK cells. The day of differentiation was recorded as D0. During differentiation, the cells were divided into two groups: one group was treated with ASV, with 1 μM ASV added to the culture medium starting on D35 and continued until D43; the other group was a control group, without ASV treatment. Both groups of cells were cultured in an incubator at 37°C and 5% CO2, with the culture medium and differentiation factors added periodically according to the differentiation protocol.
[0235] Starting from day 35, cells were collected at time points 36, 39, and 43, and BCMA.CAR expression was detected by flow cytometry. After day 43, ASV treatment was stopped, cells were cultured again, and BCMA.CAR expression was detected again at time points 45 and 50 to observe the maintenance of expression after drug withdrawal. Before each assay, cells were washed with PBS, resuspended in flow cytometry buffer, and the proportion of BCMA.CAR-positive cells was recorded.
[0236] The experimental results showed that the BCMA.CAR expression rate in the ASV drug treatment group exceeded 75% at D39 (4 days after drug administration) and further increased to over 98% at D43 (8 days after drug administration), indicating that ASV drug can efficiently induce BCMA.CAR gene expression during NK cell differentiation. The BCMA.CAR expression rate in the control group remained below 1% throughout the experiment, indicating that the BCMA.CAR gene expression control system 2 effectively inhibited BCMA.CAR expression in the absence of ASV drug treatment.
[0237] At day 43, the BCMA.CAR expression rate in the ASV-treated group reached over 98%, indicating that the induction effect peaked during differentiation. After ASV treatment was stopped, the BCMA.CAR expression rate remained relatively stable at around 98%, without a significant decrease, demonstrating the high stability of ASV-induced BCMA.CAR expression. Flow cytometry data further confirmed that the proportion of BCMA.CAR-positive cells in the ASV-treated group was significantly higher than that in the control group, and that the induction effect was highly efficient and sustained during differentiation. (Figure 9)
[0238] Example 15 Construction of a cell line stably expressing the BCMA.CAR gene system
[0239] First, a gRNA sequence targeting the H11 safety site in ES cells was designed and synthesized (the nucleic acid sequence encoding the gRNA is shown in SEQ ID NO:36), and then combined with the CRISPR / Cas12b system to construct a gene editing vector. Simultaneously, a homologous recombination donor vector containing the CAG promoter-BCMA.CAR gene expression cassette was constructed, ensuring that both ends of the donor vector contained sequences homologous to the H11 site for precise integration. The CRISPR / Cas12b vector, homologous recombination donor vector, and gRNA plasmid were mixed at a mass ratio of 2:4:1, totaling 6 μg, in P3 Buffer (82 μL P3 + 18 μL supplement) (electroporation kit: P3 Primary Cell). Using the X Kit, carefully add the cell mixture to the electroporation cuvette. The electroporation program is CA137. After electroporation, transfer the cells to 6-well plates for culture. After approximately 6 days of culture, BCMA.CAR-positive cells are sorted into 96-well plates. About one week later, single clones are passaged and expanded. Once a certain cell number has been reached, individual clones are analyzed by flow cytometry for BCMA.CAR positivity to screen for high-expressing single-clonal cell lines. (Figure 10)
[0240] Example 16: Analysis of the maturity (CD56 ratio) of the BCMA.CAR gene expression control system 2 during ES to NK differentiation.
[0241] First, single-clonal cells were selected from an ES cell line stably expressing the BCMA.CAR gene expression control system 2 and expanded to ensure a sufficient number of cells for subsequent differentiation experiments. Then, following the standard procedure for differentiating ES cells into NK cells, the expanded single-clonal cells were induced to differentiate into NK cells. During differentiation, the culture medium was changed periodically and necessary differentiation factors were added to promote cell maturation towards NK cells. The day of differentiation was recorded as D0.
[0242] During differentiation, cells were collected at different time points, and CD56 expression was detected using flow cytometry to assess NK cell maturity. Before each assay, cells were washed with PBS, resuspended in flow cytometry buffer, stained with anti-CD56 antibody, and the proportion of CD56-positive cells was recorded. Undifferentiated ES cells were used as a negative control to ensure the accuracy of the results.
[0243] The experimental results showed that the proportion of CD56-positive cells gradually increased with the progression of differentiation. At D25, the proportion of CD56-positive cells was low, indicating that the cells had not yet fully matured into NK cells. In mid-differentiation (D25-D40), the proportion of CD56-positive cells increased significantly, indicating that the cells gradually acquired the NK cell phenotype. In late differentiation, the proportion of CD56-positive cells exceeded 96%, indicating that the vast majority of cells had successfully differentiated into mature NK cells. (Figure 11A)
[0244] Example 17: Viability analysis of BCMA.CAR gene expression control system 2 during ES to NK differentiation.
[0245] First, single-clonal cells were selected from an ES cell line stably expressing the BCMA.CAR gene expression control system 2 and expanded to ensure a sufficient number of cells for subsequent differentiation experiments. Then, following the standard procedure for differentiating ES cells into NK cells, the expanded single-clonal cells were induced to differentiate into NK cells. During differentiation, the culture medium was changed periodically and necessary differentiation factors were added to promote cell maturation towards NK cells. The day of differentiation was recorded as D0.
[0246] During differentiation, cells were collected at different time points and stained with AO / PI staining solution to assess cell viability. The specific procedure was as follows: the cell suspension was mixed with AO / PI staining solution and incubated at room temperature in the dark for 5-10 minutes. Then, a cell counter or fluorescence microscope was used to count live and dead cells. Each assay was repeated at least three times, and the average value was taken as the final result.
[0247] The experimental results showed that cell viability remained at a high level throughout the differentiation process. In the later stages of differentiation, cell viability stabilized above 90%, indicating that the differentiated NK cells possessed high activity and were in good condition. (Figure 11B)
[0248] Example 18: Analysis of the maturity (CD56 ratio) of the BCMA.CAR gene stable expression system during ES to NK differentiation.
[0249] First, monoclonal cells were selected from an ES cell line stably expressing the BCMA.CAR gene system and expanded to ensure a sufficient number of cells for subsequent differentiation experiments. Then, following the standard procedure for differentiating ES cells into NK cells, the expanded monoclonal cells were induced to differentiate into NK cells. During differentiation, the culture medium was changed regularly and necessary differentiation factors were added to promote cell maturation towards NK cells. The day of differentiation was recorded as D0.
[0250] During differentiation, cells were collected at different time points, and CD56 expression was detected using flow cytometry to assess NK cell maturity. Before each assay, cells were washed with PBS, resuspended in flow cytometry buffer, stained with anti-CD56 antibody, and the proportion of CD56-positive cells was recorded. Undifferentiated ES cells were used as a negative control to ensure the accuracy of the results.
[0251] The experimental results showed that the proportion of CD56-positive cells gradually increased with the progression of differentiation. In the early differentiation stage (D25), the proportion of CD56-positive cells was low, indicating that the cells had not yet fully matured into NK cells. In the mid-differentiation stage (D25-D35), the proportion of CD56-positive cells increased significantly, indicating that the cells gradually acquired the NK cell phenotype. In the late differentiation stage (D35), the proportion of CD56-positive cells exceeded 97%, indicating that the vast majority of cells had successfully differentiated into mature NK cells. (Figure 12A)
[0252] Example 19: Viability analysis of the BCMA.CAR gene stable expression system during ES to NK differentiation.
[0253] First, monoclonal cells were selected from an ES cell line stably expressing the BCMA.CAR gene system and expanded to ensure a sufficient number of cells for subsequent differentiation experiments. Then, following the standard procedure for differentiating ES cells into NK cells, the expanded monoclonal cells were induced to differentiate into NK cells. During differentiation, the culture medium was changed regularly and necessary differentiation factors were added to promote cell maturation towards NK cells. The day of differentiation was recorded as D0.
[0254] During differentiation, cells were collected at different time points and stained with AO / PI staining solution to assess cell viability. The specific procedure was as follows: the cell suspension was mixed with AO / PI staining solution and incubated at room temperature in the dark for 5-10 minutes. Then, a cell counter or fluorescence microscope was used to count live and dead cells. Each assay was repeated at least three times, and the average value was taken as the final result.
[0255] The experimental results showed that cell viability remained at a high level throughout the differentiation process. In the later stages of differentiation, cell viability stabilized above 90%, indicating that the differentiated NK cells possessed high activity and were in good condition. (Figure 12B)
[0256] Example 20: BCMA antigen detection was performed on the target cells K562, Jeko-1, and U266 used in this invention.
[0257] First, K562, Jeko-1, and U266 cells were cultured in suitable medium to an appropriate density, ensuring the cells were in the logarithmic growth phase to guarantee experimental accuracy. After cell culture, single-cell digestion was performed using trypsin or other appropriate digestive enzymes to detach the cells from the culture dish. Digestion time was strictly controlled to avoid excessive cell damage. After digestion, the cell suspension was transferred to centrifuge tubes and centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded, and the cells were resuspended in an appropriate amount of PBS or culture medium. Subsequently, the cells were counted using a hemocytometer or automated cell counter to ensure accurate cell concentration. 5 × 10⁶ cells were collected. 5Several cells were used for subsequent experiments. Next, the cells were stained with BCMA-specific antibodies at the concentration and time recommended in the manufacturer's instructions. The staining process was performed at 4°C in the dark to reduce non-specific binding and antibody degradation. After staining, the cells were washed with PBS to remove unbound antibodies and resuspended in flow cytometry buffer. Finally, the cells were analyzed using a flow cytometer, with appropriate voltage and compensation settings to ensure data accuracy.
[0258] Flow cytometry analysis showed that the BCMA antigen positivity rate of Jeko-1 and U266 cells was ≥97%, indicating that these two cell lines highly express BCMA antigen and are suitable as positive target cells for BCMA.CAR. In contrast, the BCMA antigen positivity rate of K562 cells was 0, indicating that this cell line does not express BCMA antigen and is suitable as a negative control target cell for BCMA.CAR. Figure 13 shows the flow cytometry results, intuitively reflecting the expression of BCMA antigen in different cell lines. These results provide a reliable experimental basis for the subsequent functional validation of BCMA.CAR, ensuring the scientific nature of the experimental design and the reliability of the results (Figure 13).
[0259] Example 21: In vitro killing effect of BCMA.CAR gene expression control system 2 and ES-NK (after cryopreservation and thawing) derived from stable expression system on K562 cells.
[0260] First, cryopreserved ES-NK cells derived from the BCMA.CAR gene expression control system 2 and stable expression system were thawed. After thaw, the cells were transferred to preheated complete culture medium and incubated statically at 37°C with 5% CO2 to restore their viability. Simultaneously, K562 cells were prepared as target cells, ensuring they were in the logarithmic growth phase. K562 cells were seeded into 96-well plates, with a specific number of cells seeded per well (the exact number determined according to the experimental design). After the ES-NK cells regained viability, cell counting was performed, and the cell concentration was adjusted to the desired effector-to-target ratio (1:1 and 3:1).
[0261] ES-NK cells were added to 96-well plates pre-seeded with K562 cells, with replicates for each group to ensure the reliability of the results. The 96-well plates were placed in an Incucyte real-time live cell analyzer, and real-time monitoring was initiated. During the experiment, the Incucyte system automatically recorded changes in cell number and morphology, generating dynamic killing curves. The positive control group used BCMA CAR-T cells and underwent the same experimental procedure.
[0262] The killing effect of ES-NK cells derived from the BCMA.CAR gene expression control system 2 and the stable expression system on K562 cells was dynamically monitored using the Incucyte real-time live cell analysis system. The results showed that ES-NK cells exhibited significant killing activity at effector-to-target ratios of 1:1 and 3:1, and the killing effect further increased with increasing effector-to-target ratio. Compared with the positive control group BCMA.CAR-T cells, the killing efficiency of ES-NK cells was similar, indicating that the BCMA.CAR gene was successfully expressed and functioned in ES-NK cells. Figure 14 shows the killing curves of ES-NK cells on K562 cells at different effector-to-target ratios, visually reflecting the dynamic changes in the killing effect. (Figure 14)
[0263] Example 22: In vitro killing effect of BCMA.CAR gene expression control system 2 and ES-NK (after cryopreservation and thawing) derived from stable expression system on Jeko-1 cells.
[0264] First, cryopreserved BCMA.CAR gene expression control system 2 and stable expression system-derived ES-NK cells were revived. After revival, the cells were transferred to preheated complete culture medium and incubated statically at 37°C with 5% CO2 to restore their activity and function. Simultaneously, Jeko-1 cells were prepared as target cells, ensuring they were in the logarithmic growth phase. Jeko-1 cells were seeded into 96-well plates, with a specific number of cells seeded per well (the exact number determined according to the experimental design). After the ES-NK cells regained activity, cell counts were performed, and the cell concentration was adjusted to the desired effector-to-target ratio (1:1 and 3:1).
[0265] ES-NK cells were added to 96-well plates pre-seeded with Jeko-1 cells, with replicates for each group to ensure the reliability of the results. The 96-well plates were placed in an Incucyte real-time live cell analyzer, and real-time monitoring was initiated. During the experiment, the Incucyte system automatically recorded changes in cell number and morphology, generating dynamic killing curves. The positive control group used BCMA CAR-T cells and underwent the same experimental procedure.
[0266] The killing effect of ES-NK cells derived from the BCMA.CAR gene expression control system 2 and the stable expression system on Jeko-1 cells was dynamically monitored using the Incucyte real-time live cell analysis system. The results showed that ES-NK cells exhibited significant killing activity at effector-to-target ratios of 1:1 and 3:1, and the killing effect further increased with increasing effector-to-target ratio. Compared with the positive control group BCMA.CAR-T cells, the killing efficiency of ES-NK cells was similar, indicating that the BCMA.CAR gene was successfully expressed and functioned in ES-NK cells. Figure 15 shows the killing curves of ES-NK cells on Jeko-1 cells at different effector-to-target ratios, visually reflecting the dynamic changes in the killing effect. (Figure 15)
[0267] Example 23: In vitro killing effect of BCMA.CAR gene expression control system 2 and ES-NK (after cryopreservation and thawing) derived from stable expression system on U266 cells.
[0268] First, cryopreserved ES-NK cells derived from the BCMA.CAR gene expression control system 2 and stable expression system were thawed. After thaw, the cells were transferred to preheated complete culture medium and incubated statically at 37°C with 5% CO2 to restore their activity and function. Simultaneously, U266 cells were prepared as target cells, ensuring they were in the logarithmic growth phase. U266 cells were seeded into 96-well plates, with a specific number of cells seeded per well (the exact number determined according to the experimental design). After the ES-NK cells regained activity, cell counts were performed, and the cell concentration was adjusted to the desired effector-to-target ratio (1:1 and 3:1).
[0269] ES-NK cells were added to 96-well plates pre-seeded with U266 cells, with replicates for each group to ensure the reliability of the results. The 96-well plates were placed in an Incucyte real-time live cell analyzer, and real-time monitoring was initiated. During the experiment, the Incucyte system automatically recorded changes in cell number and morphology, generating dynamic killing curves. The positive control group used BCMA CAR-T cells and underwent the same experimental procedure.
[0270] The killing effect of ES-NK cells derived from the BCMA.CAR gene expression control system 2 and the stable expression system on U266 cells was dynamically monitored using the Incucyte real-time live cell analysis system. The results showed that ES-NK cells exhibited significant killing activity at effector-to-target ratios of 1:1 and 3:1, with the killing effect further enhanced with increasing effector-to-target ratio. Compared with the positive control group BCMA.CAR-T cells, the killing efficiency of ES-NK cells was similar, indicating that the BCMA.CAR gene was successfully expressed and functioned in ES-NK cells. Figure 16 shows the killing curves of ES-NK cells on U266 cells at different effector-to-target ratios, visually reflecting the dynamic changes in the killing effect. These results indicate that ES-NK cells, after cryopreservation and thawing, still possess good activity and killing ability, providing reliable data support for subsequent in vivo experiments and clinical applications. (Figure 16)
[0271] Example 24: Analysis of the impact of TGFβ on ES-NK function
[0272] First, prepare ES-NK cells and K562 cells, ensuring both are in the logarithmic growth phase. Seed K562 cells into 96-well plates, with a specific number of cells seeded per well (the exact number depends on the experimental design). Simultaneously, divide the ES-NK cells into two groups: one group receives medium containing TGFβ (experimental group), and the other group receives medium without TGFβ (control group). Add the ES-NK cells to the 96-well plates seeded with K562 cells, with replicates for each group to ensure the reliability of the experimental results. Place the 96-well plates in an Incucyte real-time live cell analyzer and start real-time monitoring. The experiment is conducted in 24-hour cycles. After each cycle, fresh K562 target cells are replenished to maintain a consistent effector-to-target ratio. The experiment continues for multiple cycles; the Incucyte system automatically records cell number and morphological changes, generating dynamic killing curves.
[0273] The killing function of ES-NK cells against K562 cells with and without TGFβ treatment was dynamically monitored using the Incucyte real-time live cell analysis system. Results showed that during the first cycle, there was no significant difference in the killing effect of ES-NK cells against K562 cells between the experimental group (with TGFβ) and the control group (without TGFβ). However, starting from the second cycle, the killing function of ES-NK cells in the experimental group significantly decreased, while the control group maintained stable killing activity. With increasing experimental cycles, the inhibitory effect of TGFβ on ES-NK cell function gradually increased. Figure 17 shows the killing curves of ES-NK cells against K562 cells at different cycles, visually reflecting the inhibitory effect of TGFβ on ES-NK cell function. These results indicate that TGFβ significantly inhibits the function of ES-NK cells over long-term effects, providing important evidence for further research on the regulatory mechanism of TGFβ on immune cell function. (Figure 17)
[0274] Example 25: Tolerance of TGFβ treatment to ES-NK cells derived from the TGFBRc gene expression control system 2
[0275] First, prepare ES-NK cells and wild-type ES-NK cells derived from the TGFBRc gene expression control system 2, as well as K562 cells, ensuring all cells are in the logarithmic growth phase. Seed K562 cells into 96-well plates, with a specific number of cells seeded per well (the exact number determined according to the experimental design). Divide the ES-NK cells from the TGFBRc gene expression control system 2 and wild-type ES-NK cells into two groups: one group is treated with culture medium containing TGFβ (experimental group), and the other group is treated with culture medium without TGFβ (control group). Add ES-NK cells to the 96-well plates seeded with K562 cells, with replicates for each group to ensure the reliability of the experimental results. Place the 96-well plates in an Incucyte real-time live cell analyzer and start real-time monitoring. The experiment is conducted in 24-hour cycles. After each cycle, fresh K562 target cells are replenished to maintain a consistent effector-to-target ratio. The experiment continues for multiple cycles, and the Incucyte system automatically records cell number and morphological changes, generating dynamic killing curves.
[0276] The cytotoxic effects of ES-NK cells derived from the TGFBRc gene expression control system 2 and wild-type ES-NK cells on K562 cells were dynamically monitored using the Incucyte real-time live-cell analysis system under conditions of TGFβ treatment and without. The results showed that during the first cycle, there was no significant difference in cytotoxicity of K562 cells between ES-NK cells derived from the TGFBRc gene expression control system 2 and wild-type ES-NK cells under TGFβ treatment. However, starting from the second cycle, the cytotoxic function of wild-type ES-NK cells significantly decreased under TGFβ treatment, while ES-NK cells derived from the TGFBRc gene expression control system 2 showed some resistance to TGFβ inhibition, with a significantly smaller decrease in cytotoxicity compared to wild-type ES-NK cells. With increasing experimental cycles, the inhibitory effect of TGFβ on the function of wild-type ES-NK cells gradually increased, while ES-NK cells derived from the TGFBRc gene expression control system 2 maintained relatively high cytotoxic activity. Figure 18 shows the killing curves of two types of ES-NK cells against K562 cells at different cell cycles, intuitively reflecting the resistance effect of the TGFBRc gene expression control system 2 to the inhibition of TGFβ. (Figure 18)
[0277] Example 26: Treatment of Jeko-1 tumor model with ES-NK (frozen and thawed) derived from BCMA.CAR gene expression control system 2 (presented as in vivo optical imaging data of small animals).
[0278] First, NSG immunodeficient mice (lacking T, B, and NK cells) were selected as the experimental animal model. A leukemia animal model was established by tail vein injection of the human mantle cell lymphoma cell line Jeko-1. Two days after tumor cell inoculation, mice were randomly divided into three groups: Group 1 was the negative control group, receiving PBS injection; Group 2 was the single-dose group, receiving one injection of ES-NK cells derived from the BCMA.CAR gene expression control system 2; and Group 3 was the multiple-dose group, receiving six injections of ES-NK cells derived from the BCMA.CAR gene expression control system 2. The day of grouping was defined as D0. Groups 1 and 3 were administered the drugs via tail vein at different time points, while Group 2 received only one tail vein injection on D0. The cell dose injected each time was 2.5 × 10^7 cells / mouse. During the experiment, small animal in vivo optical imaging technology was used to regularly monitor the growth changes of tumors in mice. Before in vivo imaging, a luciferase substrate (D-luciferin) was injected intraperitoneally to induce fluorescence in tumor cells, facilitating capture and analysis by the imaging system.
[0279] The growth of tumors in mice was dynamically monitored using in vivo optical imaging technology in small animals. The results showed that mice treated with ES-NK cells derived from the BCMA.CAR gene expression control system 2 (whether treated with 1 or 6 doses) exhibited significant tumor inhibition compared to the negative control group (PBS group). The single-dose group (1 dose) showed some tumor inhibition in the early stages, but tumor growth gradually recovered over time. The multi-dose group (6 doses) showed stronger tumor inhibition throughout the experimental period, with significantly slower tumor growth and significantly lower fluorescence signal intensity than the single-dose group and the negative control group. Figure 19 shows the fluorescence imaging results of tumors in mice at different time points, visually reflecting the dynamic changes in tumor growth. These results indicate that ES-NK cells derived from the BCMA.CAR gene expression control system 2 have a significant inhibitory effect on Jeko-1 tumors in vivo, and that multi-dose treatment is more effective than single-dose treatment, providing important experimental evidence for subsequent clinical studies. (Figure 19)
[0280] Example 27: Treatment of Jeko-1 tumor model with ES-NK (frozen and thawed) derived from BCMA.CAR gene expression control system 2 (presented as luminescence intensity data from in vivo optical imaging of small animals).
[0281] First, NSG immunodeficient mice (lacking T, B, and NK cells) were selected as the experimental animal model. A leukemia animal model was established by tail vein injection of the human mantle cell lymphoma cell line Jeko-1. Two days after tumor cell inoculation, mice were randomly divided into three groups: Group 1 was the negative control group, receiving PBS injection; Group 2 was the single-dose group, receiving one injection of ES-NK cells derived from the BCMA.CAR gene expression control system 2; and Group 3 was the multiple-dose group, receiving six injections of ES-NK cells derived from the BCMA.CAR gene expression control system 2. The day of grouping was defined as D0. Groups 1 and 3 were administered the drugs via tail vein at different time points, while Group 2 received only one tail vein injection on D0. The cell dose injected each time was 2.5 × 10^7 cells / mouse. During the experiment, small animal in vivo optical imaging technology was used to regularly monitor the growth changes of tumors in mice. Before in vivo imaging, a luciferase substrate (D-luciferin) was injected intraperitoneally to induce fluorescence in tumor cells, facilitating capture and analysis by the imaging system. Simultaneously, the luminescence intensity of in vivo optical imaging of small animals was quantitatively recorded to assess changes in tumor burden.
[0282] The growth of tumors in mice was dynamically monitored using small animal in vivo optical imaging technology, and the changes in luminescence intensity were quantitatively analyzed. The results showed that mice treated with ES-NK cells derived from the BCMA.CAR gene expression control system 2 (whether treated with 1 or 6 doses) exhibited significant tumor inhibition compared to the negative control group (PBS group). The single-dose group (1 dose) showed some tumor inhibition in the early stages, but tumor growth gradually recovered over time, and the luminescence intensity rebounded. The multi-dose group (6 doses) showed stronger tumor inhibition throughout the experimental period, with significantly lower luminescence intensity than the single-dose group and the negative control group, indicating a significant reduction in tumor burden. Figure 20 shows the quantitative data of tumor luminescence intensity in mice at different time points, visually reflecting the dynamic changes in tumor growth. These results indicate that ES-NK cells derived from the BCMA.CAR gene expression control system 2 have a significant inhibitory effect on Jeko-1 tumors in vivo, and that multi-dose treatment is more effective than single-dose treatment, providing important experimental evidence for subsequent clinical studies. (Figure 20)
[0283] Example 28: Pharmacokinetics (PK) of a single treatment of a Jeko-1 tumor model with BCMA.CAR gene expression control system 2 and ES-NK derived from a stable expression system.
[0284] First, NSG immunodeficient mice (lacking T, B, and NK cells) were selected as the experimental animal model. A leukemia animal model was established by tail vein injection of the human mantle cell lymphoma cell line Jeko-1. Two days after tumor cell inoculation, mice were randomly divided into three groups: Group 1 was the negative control group, receiving PBS injection; Group 2 received an injection of ES-NK cells derived from the BCMA.CAR gene expression control system 2 (1 dose); and Group 3 received an injection of ES-NK cells derived from the BCMA.CAR gene stable expression system (1 dose). The day of grouping was defined as D0. All groups received tail vein injections on D0, with a cell dose of 2.5 × 10^7 cells / mouse per injection. Peripheral blood samples were collected from mice at different time points, and the number and viability of the infused ES-NK cells were detected by flow cytometry. During flow cytometry, specific antibodies were used to label ES-NK cells to distinguish them from endogenous mouse cells.
[0285] Analysis of peripheral blood samples by flow cytometry revealed that ES-NK cells derived from the BCMA.CAR gene expression control system 2 exhibited higher and more sustained survival and expansion capabilities in vivo, demonstrating superior pharmacokinetic characteristics compared to ES-NK cells derived from the stable expression system of the BCMA.CAR gene. Specifically, the number of ES-NK cells from the BCMA.CAR gene expression control system 2 was significantly higher at early time points than that from the stable expression system, and this higher number was maintained at subsequent time points, indicating stronger persistence and expansion capabilities in vivo. In contrast, the ES-NK cells from the stable expression system showed lower survival time and numbers in vivo. Figure 21 illustrates the changes in the number of ES-NK cells in peripheral blood at different time points, visually reflecting the differences in pharmacokinetics. These results suggest that ES-NK cells derived from the BCMA.CAR gene expression control system 2 possess greater pharmacodynamic potential, providing important experimental evidence for optimizing CAR-NK cell therapy strategies. (Figure 21)
[0286] Example 29: Gene editing strategy, cell line construction, and induction test of the GFP gene expression control system 3
[0287] Gene expression frames for Part 1 and Part 2 were constructed based on the sequence information in the sequence listing. The GFP gene expression control system 3 consists of two parts. The first part includes a CAG promoter-Cre structure 3 splitting gene expression cassette-CAG promoter-mCherry-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5; the Cre structure 3 splitting nucleic acid sequence is shown in SEQ ID NO:41, which contains the nucleic acid sequence encoding the wild-type NS3 protease with the amino acid sequence SEQ ID NO:37; the mCherry-Tag nucleic acid sequence is shown in SEQ ID NO:20), and the Cre splitting site of the Cre structure 3 splitting is located between positions 244 and 245 of SEQ ID NO:22. The second part includes a CAG promoter-Loxp-Stop-Loxp-GFP gene expression cassette-CAG promoter-BFP-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5, the Loxp-Stop-Loxp nucleic acid sequence is shown in SEQ ID NO:10, the GFP nucleic acid sequence is shown in SEQ ID NO:12, and the BFP-Tag nucleic acid sequence is shown in SEQ ID NO:41). (See NO:7) (Figure 22). All sequences were synthesized at Genscript Biotech Ltd., as shown in the sequence listing.
[0288] Using the laboratory Piggybac with ampicillin resistance backbone (SEQ ID NO:21) as a vector, PCR was performed on the CAG promoter-Cre structure 3 gene expression cassette split using primers F1 (SEQ ID NO:27) and R1 (SEQ ID NO:28), and on the CAG promoter-mCherry-Tag using primers F2 (SEQ ID NO:29) and R2 (SEQ ID NO:30). The two PCR products were then infused with the linearized Piggybac with ampicillin resistance backbone vector to obtain the recombinant plasmid CAG promoter-Cre structure 3 gene expression cassette split-CAG promoter-mCherry-Tag. PCR was performed on the CAG promoter-Loxp-Stop-Loxp-GFP gene expression cassette using primers F3 (SEQ ID NO:31) and R3 (SEQ ID NO:32), and on the CAG promoter-BFP-Tag using primers F4 (SEQ ID NO:33) and R4 (SEQ ID NO:34). The two PCR products were then infused with a linearized Piggybac vector containing ampicillin resistance, resulting in a recombinant plasmid named CAG promoter-Loxp-Stop-Loxp-GFP gene expression cassette-CAG promoter-BFP-Tag. The two components were then integrated into the genome of ES cells using the Piggybac integration method.
[0289] Culture ES cells to a suitable density (usually 70-80% confluence), digest single cells using TrypLE or other appropriate digestion solutions, centrifuge (e.g., 1000 rpm, 5 min) and resuspend the cells in fresh culture medium, stain the cells with AO / PI staining solution, count the viable cells using an automated cell counter, record the viable cell concentration, transfer 1.5e6 cells to a 1.5 mL centrifuge tube, centrifuge again at 100 rpm / 5 min to remove the supernatant.
[0290] Add 6 μg of the plasmid (Piggybac enzyme plasmid: Part 1 plasmid: Part 2 plasmid = 1:1:1) to P3 Buffer (82 μL P3 + 18 μL supplement) and mix well (electroporation kit: P3 Primary Cell). Using the X Kit, carefully add the cell mixture to an electroporation cuvette. Electroporation is performed using the CA137 program. After electroporation, transfer the cells to 6-well plates for culture. After approximately 6 days of culture, sort the cells for mCherry-Tag and BFP-Tag positivity. About one week later, passage and expand the enriched positive cells. Once a sufficient number of cells have been reached, flow cytometry analysis is performed to detect the expression of mCherry-Tag, BFP-Tag, and the control gene GFP.
[0291] In the absence of ASV treatment, cells expressed mCherry-Tag and BFP-Tag, but not GFP (Figure 26). This result demonstrates the successful construction of an ES cell line expressing the GFP gene expression control system 3. Even though this cell line only partially expresses the GFP gene expression control system 3, it does not affect the evaluation of this system. This system stably expresses mCherry-Tag and BFP-Tag without ASV treatment, while suppressing GFP expression, without background or leakage of expression. This system can be used to study gene expression regulation and drug-induced gene expression changes.
[0292] Cells expressing the GFP gene expression control system 3 were expanded and cultured to ensure good cell condition and a viable cell ratio greater than 90%. Subsequently, the expanded cells were seeded into 24-well plates at a density of 5 × 10^4 cells / well, with 2 mL of complete culture medium added to each well to ensure uniform cell distribution. The day of seeding was designated D0. The 24-well plates were divided into three groups: (1) ASV treatment group, with 1 μM ASV added to the culture medium at D0; (2) DAV treatment group, with 1 μM DAV added to the culture medium at D0; and (3) control group, without ASV or DAV. All three groups of cells were cultured in an incubator at 37°C and 5% CO2.
[0293] Starting from day 0, cells were collected at different time points, and GFP expression was detected using flow cytometry. After day 7, ASV or DAV treatment was stopped. Before each assay, cells were washed with PBS, resuspended in flow cytometry buffer, and the proportion of GFP-positive cells was detected and recorded.
[0294] The experimental results showed that the GFP expression rate in the ASV and DAV drug treatment groups was close to 90% on day 4, and further increased to almost 100% on day 7, indicating that NS3 protease inhibitors can efficiently induce GFP gene expression. The GFP expression rate in the control group remained below 1% throughout the experiment, indicating that the GFP gene expression control system 3 could effectively inhibit GFP expression in the absence of NS3 protease inhibitor treatment (Figure 27).
[0295] This experiment successfully verified the highly efficient induction effect of the NS3 protease drug on the GFP gene expression control system 3. The ASV drug significantly increased the GFP expression ratio in a short period (D4) and maintained a high expression level for a longer period (D7 and beyond). This result indicates that the GFP gene expression control system 3 has high controllability and stability.
[0296] Further testing was conducted on the induced expression effects of GFP gene expression control systems 1, 2, and 3. Stable cell lines expressing different GFP gene expression control systems (System 1, System 2, and System 3) were expanded and cultured to ensure good cell condition and a viable cell ratio of over 90%. The expanded cells were seeded at a uniform density (5 × 10^4 cells / well) in multi-well plates, and after adding complete culture medium, they were cultured at 37°C and 5% CO2. The day of seeding was recorded as day 0 (D0). All three groups of cells were supplemented with a final concentration of 1 μM ASV. Cells were then continuously cultured under the same conditions, and cells were collected from day 0 to day 7. GFP expression levels were detected by flow cytometry. The results showed that in all three expression control systems, NS3 protease inhibitors significantly increased the GFP expression ratio within a short period (D4) and maintained a high expression level for a longer period (D7 and beyond) (Figure 28). This result indicates that the three gene expression control systems have high controllability and stability.
[0297] Example 30: Gene editing strategy, cell line construction, and induction test of the GFP gene expression control system 4
[0298] Gene expression frames for Part 1 and Part 2 were constructed based on the sequence information in the sequence listing. The GFP gene expression control system 4 consists of two parts. The first part includes a CAG promoter-Cre structure 4 split gene expression box-CAG promoter-mCherry-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5; the nucleic acid sequence of the split Cre structure 4 is shown in SEQ ID NO:43, which contains a nucleic acid sequence encoding the 3CLpro protease with the amino acid sequence SEQ ID NO:38; the mCherry-Tag nucleic acid sequence is shown in SEQ ID NO:20), and the Cre split site of the split Cre structure 4 is located between positions 244 and 245 of SEQ ID NO:22. The second part includes a CAG promoter-Loxp-Stop-Loxp-GFP gene expression box-CAG promoter-BFP-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5, the Loxp-Stop-Loxp nucleic acid sequence is shown in SEQ ID NO:10, the GFP nucleic acid sequence is shown in SEQ ID NO:12, and the BFP-Tag nucleic acid sequence is shown in SEQ ID NO:20). (See NO:7) (Figure 22). All sequences were synthesized at Genscript Biotech Ltd., as shown in the sequence listing.
[0299] Using the laboratory Piggybac with ampicillin resistance backbone (SEQ ID NO:21) as a vector, PCR was performed on the CAG promoter-Cre structure 3 gene expression cassette split using primers F1 (SEQ ID NO:27) and R1 (SEQ ID NO:28), and on the CAG promoter-mCherry-Tag using primers F2 (SEQ ID NO:29) and R2 (SEQ ID NO:30). The two PCR products were then infused with the linearized Piggybac with ampicillin resistance backbone vector to obtain the recombinant plasmid CAG promoter-Cre structure 3 gene expression cassette split-CAG promoter-mCherry-Tag. PCR was performed on the CAG promoter-Loxp-Stop-Loxp-GFP gene expression cassette using primers F3 (SEQ ID NO:31) and R3 (SEQ ID NO:32), and on the CAG promoter-BFP-Tag using primers F4 (SEQ ID NO:33) and R4 (SEQ ID NO:34). The two PCR products were then infused with a linearized Piggybac vector containing ampicillin resistance, resulting in a recombinant plasmid named CAG promoter-Loxp-Stop-Loxp-GFP gene expression cassette-CAG promoter-BFP-Tag. The two components were then integrated into the genome of ES cells using the Piggybac integration method.
[0300] Culture ES cells to a suitable density (usually 70-80% confluence), digest single cells using TrypLE or other appropriate digestion solutions, centrifuge (e.g., 1000 rpm, 5 min) and resuspend the cells in fresh culture medium, stain the cells with AO / PI staining solution, count the viable cells using an automated cell counter, record the viable cell concentration, transfer 1.5e6 cells to a 1.5 mL centrifuge tube, centrifuge again at 100 rpm / 5 min to remove the supernatant.
[0301] Add 6 μg of the plasmid (Piggybac enzyme plasmid: Part 1 plasmid: Part 2 plasmid = 1:1:1) to P3 Buffer (82 μL P3 + 18 μL supplement) and mix well (electroporation kit: P3 Primary Cell). Using the X Kit, carefully add the cell mixture to an electroporation cuvette. Electroporation is performed using the CA137 program. After electroporation, transfer the cells to 6-well plates for culture. After approximately 6 days of culture, sort the cells for mCherry-Tag and BFP-Tag positivity. About one week later, passage and expand the enriched positive cells. Once a sufficient number of cells have been reached, flow cytometry analysis is performed to detect the expression of mCherry-Tag, BFP-Tag, and the control gene GFP.
[0302] The results showed that, without treatment with 3CLpro enzyme inhibitors, cells expressed mCherry-Tag and BFP-Tag, but most cells also expressed GFP (Figure 29). This indicates that the gene expression control system 4 suffers from background leakage of spontaneous GFP gene expression when not treated with 3CLpro enzyme inhibitors. Therefore, this system is not suitable for studying gene expression regulation and drug-induced gene expression changes.
[0303] Example 31: Gene editing strategy, cell line construction, and induction test of the GFP gene expression control system 5
[0304] Gene expression frames for Part 1 and Part 2 were constructed based on the sequence information in the sequence listing. The GFP gene expression control system 5 consists of two parts. The first part includes a CAG promoter-Dre structure splitting gene expression cassette-CAG promoter-mCherry-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5; the nucleic acid sequence of the Dre structure splitting 5 is shown in SEQ ID NO:45, which contains a nucleic acid sequence encoding the NS3 protease with the amino acid sequence SEQ ID NO:23; the mCherry-Tag nucleic acid sequence is shown in SEQ ID NO:20), and the Dre splitting site of the Dre structure splitting 5 is located between positions 246 and 247 of SEQ ID NO:39; the second part includes a CAG promoter-Rox-Stop-Rox-GFP gene expression cassette-CAG promoter-BFP-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5; the Rox-Stop-Rox nucleic acid sequence is shown in SEQ ID NO:48; the GFP nucleic acid sequence is shown in SEQ ID NO:12; the BFP-Tag nucleic acid sequence is shown in SEQ ID NO:20). (See NO:7) (Figure 25). All sequences were synthesized at Genscript Biotech Ltd., as shown in the sequence listing.
[0305] Using the laboratory Piggybac with ampicillin resistance backbone (SEQ ID NO:21) as a vector, PCR was performed on the CAG promoter-split Dre structure 5 gene expression cassette using primers F1 (SEQ ID NO:27) and R1 (SEQ ID NO:28), and on the CAG promoter-mCherry-Tag using primers F2 (SEQ ID NO:29) and R2 (SEQ ID NO:30). The two PCR products were infused and ligated with the linearized Piggybac with ampicillin resistance backbone vector to obtain the recombinant plasmid CAG promoter-split Dre structure 5 gene expression cassette-CAG promoter-mCherry-Tag. PCR was performed on the CAG promoter-Rox-Stop-Rox-GFP gene expression cassette using primers F3 (SEQ ID NO:31) and R3 (SEQ ID NO:32), and on the CAG promoter-BFP-Tag using primers F4 (SEQ ID NO:33) and R4 (SEQ ID NO:34). The two PCR products were then infused with a linearized Piggybac vector containing ampicillin resistance, resulting in a recombinant plasmid named CAG promoter-Rox-Stop-Rox-GFP gene expression cassette-CAG promoter-BFP-Tag. The two components were then integrated into the genome of ES cells using the Piggybac integration method.
[0306] Culture ES cells to a suitable density (usually 70-80% confluence), digest single cells using TrypLE or other appropriate digestion solutions, centrifuge (e.g., 1000 rpm, 5 min) and resuspend the cells in fresh culture medium, stain the cells with AO / PI staining solution, count the viable cells using an automated cell counter, record the viable cell concentration, transfer 1.5e6 cells to a 1.5 mL centrifuge tube, centrifuge again at 100 rpm / 5 min to remove the supernatant.
[0307] Add 6 μg of the plasmid (Piggybac enzyme plasmid: Part 1 plasmid: Part 2 plasmid = 1:1:1) to P3 Buffer (82 μL P3 + 18 μL supplement) and mix well (electroporation kit: P3 Primary Cell). Using the X Kit, carefully add the cell mixture to an electroporation cuvette. Electroporation is performed using the CA137 program. After electroporation, transfer the cells to 6-well plates for culture. After approximately 6 days of culture, sort the cells for mCherry-Tag and BFP-Tag positivity. About one week later, passage and expand the enriched positive cells. Once a sufficient number of cells have been reached, flow cytometry analysis is performed to detect the expression of mCherry-Tag, BFP-Tag, and the control gene GFP.
[0308] In the absence of ASV treatment, cells expressed mCherry-Tag and BFP-Tag, but not GFP (Figure 30). These results demonstrate the successful construction of an ES cell line expressing a GFP gene expression control system 5. This system stably expresses mCherry-Tag and BFP-Tag without ASV treatment, while simultaneously inhibiting GFP expression without background or leakage. This system can be used to study gene expression regulation and drug-induced gene expression changes.
[0309] Cells expressing the GFP gene expression control system 5 were expanded and cultured to ensure good cell condition and a viable cell ratio greater than 90%. Subsequently, the expanded cells were seeded into 24-well plates at a density of 5 × 10^4 cells / well, with 2 mL of complete culture medium added to each well to ensure uniform cell distribution. The day of seeding was designated D0. The 24-well plates were divided into two groups: (1) the ASV drug treatment group, where ASV drug was added to the culture medium at a final concentration of 1 μM on D0; and (2) the control group, where no ASV or DAV drug was added. Both groups of cells were cultured in an incubator at 37°C and 5% CO2.
[0310] Starting from day 0, cells were collected at different time points, and GFP expression was detected using flow cytometry. ASV treatment was stopped after day 9. Before each assay, cells were washed with PBS, resuspended in flow cytometry buffer, and the proportion of GFP-positive cells was detected and recorded.
[0311] The experimental results showed that the GFP expression rate in the ASV drug treatment group did not exceed 5%, indicating that the induction regulation system 5 lacked responsiveness to NS3 protease inhibitors (such as ASV), and its induction regulation level was comparable to that of the control group (without ASV drug treatment) (Figure 31). This indicates that the system failed to achieve the expected expression regulation after the addition of the corresponding protease inhibitor, exhibiting persistent low expression or an expression-off state. Therefore, the regulation system 5 does not possess the induction regulation function based on the NS3 protease inhibition mechanism.
[0312] Example 32: Gene editing strategy, cell line construction, and induction testing of the GFP gene expression control system 6
[0313] Gene expression frames for Part 1 and Part 2 were constructed based on the sequence information in the sequence listing. The GFP gene expression control system 6 consists of two parts. Part 1 includes a CAG promoter-Dre structure splitting 6 gene expression cassette-CAG promoter-mCherry-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5; the nucleic acid sequence of the Dre structure splitting 6 is shown in SEQ ID NO:47, which contains a nucleic acid sequence encoding the 3CLpro protease with the amino acid sequence SEQ ID NO:38; the mCherry-Tag nucleic acid sequence is shown in SEQ ID NO:20), and the Dre splitting site of the Dre structure splitting 6 is located between positions 246 and 247 of SEQ ID NO:39. Part 2 includes a CAG promoter-Rox-Stop-Rox-GFP gene expression cassette-CAG promoter-BFP-Tag (wherein the CAG promoter nucleic acid sequence is shown in SEQ ID NO:5; the Rox-Stop-Rox nucleic acid sequence is shown in SEQ ID NO:48; the GFP nucleic acid sequence is shown in SEQ ID NO:12; the BFP-Tag nucleic acid sequence is shown in SEQ ID NO:20). (See NO:7) (Figure 25). All sequences were synthesized at Genscript Biotech Ltd., as shown in the sequence listing.
[0314] Using the laboratory Piggybac with ampicillin resistance backbone (SEQ ID NO:21) as a vector, PCR was performed on the CAG promoter-split Dre structure 6 gene expression cassette using primers F1 (SEQ ID NO:27) and R1 (SEQ ID NO:28), and on the CAG promoter-mCherry-Tag using primers F2 (SEQ ID NO:29) and R2 (SEQ ID NO:30). The two PCR products were infused and ligated with the linearized Piggybac with ampicillin resistance backbone vector to obtain the recombinant plasmid CAG promoter-split Dre structure 6 gene expression cassette-CAG promoter-mCherry-Tag. PCR was performed on the CAG promoter-Rox-Stop-Rox-GFP gene expression cassette using primers F3 (SEQ ID NO:31) and R3 (SEQ ID NO:32), and on the CAG promoter-BFP-Tag using primers F4 (SEQ ID NO:33) and R4 (SEQ ID NO:34). The two PCR products were then infused with a linearized Piggybac vector containing ampicillin resistance, resulting in a recombinant plasmid named CAG promoter-Rox-Stop-Rox-GFP gene expression cassette-CAG promoter-BFP-Tag. The two components were then integrated into the genome of ES cells using the Piggybac integration method.
[0315] Culture ES cells to a suitable density (usually 70-80% confluence), digest single cells using TrypLE or other appropriate digestion solutions, centrifuge (e.g., 1000 rpm, 5 min) and resuspend the cells in fresh culture medium, stain the cells with AO / PI staining solution, count the viable cells using an automated cell counter, record the viable cell concentration, transfer 1.5e6 cells to a 1.5 mL centrifuge tube, centrifuge again at 100 rpm / 5 min to remove the supernatant.
[0316] Add 6 μg of the plasmid (Piggybac enzyme plasmid: Part 1 plasmid: Part 2 plasmid = 1:1:1) to P3 Buffer (82 μL P3 + 18 μL supplement) and mix well (electroporation kit: P3 Primary Cell). Using the X Kit, carefully add the cell mixture to an electroporation cuvette. Electroporation is performed using the CA137 program. After electroporation, transfer the cells to 6-well plates for culture. After approximately 6 days of culture, sort the cells for mCherry-Tag and BFP-Tag positivity. About one week later, passage and expand the enriched positive cells. Once a sufficient number of cells have been reached, flow cytometry analysis is performed to detect the expression of mCherry-Tag, BFP-Tag, and the control gene GFP.
[0317] Without treatment with 3CLpro protease inhibitors, over 90% of cells expressed mCherry-Tag and BFP-Tag, but a small amount of GFP expression leakage was observed (Figure 32). These results indicate that an ES cell line expressing a GFP gene expression control system has been successfully constructed. This system can be used to study gene expression regulation and drug-induced gene expression changes.
[0318] The cell line expressing the GFP gene expression control system 6 was expanded and cultured to ensure good cell condition and a viable cell ratio greater than 90%. Subsequently, the expanded cells were seeded into multi-well plates at a density of 5 × 10^4 cells / well, with 2 mL of complete culture medium added to each well to ensure uniform cell distribution. The day of seeding was recorded as D0. The multi-well plates were divided into multiple experimental groups based on the concentration of the 3CLpro enzyme inhibitor GC376 added, including: 0 μM (no drug control group), 0.5 μM, 1 μM, 2 μM, 4 μM, 8 μM, 16 μM, and 32 μM, a total of eight concentration gradient groups. All cell lines were cultured in an incubator at 37°C and 5% CO2.
[0319] Starting from day 0, cells were collected at different time points, and GFP expression was detected using flow cytometry. Drug treatment was stopped after day 7. Before each assay, cells were washed with PBS, resuspended in flow cytometry buffer, and the proportion of GFP-positive cells was detected and recorded.
[0320] The experimental results showed that the overall GFP-positive rate in each concentration treatment group remained at a low level, with only a slight upward trend over time, and remained in the low range until day 7. No clear dose-dependent relationship was observed between different concentrations, and high concentration treatment did not lead to a significant increase in expression (Figure 33). This indicates that the system failed to achieve the expected expression regulation after the addition of the corresponding protease inhibitor, exhibiting persistently low expression. Therefore, this regulatory system 6 does not possess the induction and regulation function based on the protease inhibition mechanism.
Claims
A fusion protein comprising an N-terminal fragment of a recombinase, a cleavage site, a protease, and a C-terminal fragment of a recombinase. The fusion protein according to claim 1, wherein the fusion protein comprises, from the N-terminus to the C-terminus: a) N-terminal fragment of recombinase, restriction site, protease, C-terminal fragment of recombinase; b) Recombinase N-terminal fragment, protease, restriction site, recombinase C-terminal fragment; or c) Recombinase N-terminal fragment, restriction site, protease, restriction site, recombinase C-terminal fragment. The fusion protein according to any one of claims 1-2, wherein the recombinase is selected from one or more recombinases from the group consisting of Cre recombinase, Flp recombinase and Dre recombinase. The fusion protein according to any one of claims 1-3, wherein the recombinase is Cre recombinase. The fusion protein according to any one of claims 1-4, wherein the cleavage sites of the N-terminal and C-terminal fragments of the recombinase are located in the loop-linked region of the Cre enzyme. The fusion protein according to any one of claims 3-5, wherein the Cre recombinase comprises the amino acid sequence shown in SEQ ID NO:
22. The fusion protein according to any one of claims 1-6, wherein the splitting sites of the N-terminal and C-terminal fragments of the recombinase are: between amino acid residues at positions 59 and 60, 104 and 106, 155 and 156, 180 and 196, 232 and 233, or 244 and 245 from the N-terminus. The fusion protein according to any one of claims 1-7, wherein the cleavage site of the N-terminal and C-terminal fragments of the recombinase is between amino acid residues 59 and 60 or 244 and 245 from the N-terminus. The fusion protein according to any one of claims 1-8, wherein the protease is a viral protease that can be used for protein cleavage or degradation. The fusion protein according to any one of claims 1-9, wherein the protease is selected from one or more proteases from the group consisting of NS3 protease, TEV protease and 3C / 3CL protease. The fusion protein according to any one of claims 1-10, wherein the protease is NS3 protease. The fusion protein according to any one of claims 10-11, wherein the NS3 protease comprises the amino acid sequence shown in SEQ ID NO:
23. The fusion protein according to any one of claims 1-12, wherein any two adjacent fragments of the recombinase N-terminal fragment, the restriction site, the protease, and the recombinase C-terminal fragment are directly linked. The fusion protein according to any one of claims 1-12, wherein any two adjacent fragments of the recombinase N-terminal fragment, the restriction site, the protease, and the recombinase C-terminal fragment are connected by one or more linkers. According to claim 14, the fusion protein, wherein the recombinant protein comprises, from the N-terminus to the C-terminus, the following: a) N-terminal fragment of recombinase, linker, restriction site, linker, protease, linker, C-terminal fragment of recombinase; b) N-terminal fragment of recombinase, linker, protease, linker, restriction site, linker, C-terminal fragment of recombinase; or c) Recombinase N-terminal fragment, linker, restriction site, linker, protease, linker, restriction site, linker, recombinase C-terminal fragment. The fusion protein according to any one of claims 14-15, wherein the linker comprises the amino acid sequence shown in SEQ ID NO:24 or SEQ ID NO:
25. The fusion protein according to any one of claims 1-16, wherein the fusion protein comprises the amino acid sequence shown in SEQ ID NO:1 or SEQ ID NO:
3. According to any one of claims 1-17, the fusion protein can be used to regulate the activity of the fusion protein by inhibiting the activity of the protease with a protease inhibitor. According to claim 18, the fusion protein, wherein the protease inhibitor is an NS3 protease inhibitor selected from one or more of the following groups of inhibitors: Grazoprevir (GZV), Asunaprevir (ASV), Glecaprevir (GLE), Daclatasvir (DCV), Telaprevir (TPV), Danoprevir (DAV), Vaniprevir (VAV), Ciluprevir (BILN 2061), Simeprevir (SMV), Boceprevir (BOC), Sovaprevir (SOV), and Paritaprevir (PTV). The fusion protein according to claim 19, wherein the NS3 protease inhibitor is ASV. A polypeptide comprising the fusion protein according to any one of claims 1-20. An isolated nucleic acid molecule encoding a fusion protein as described in any one of claims 1-20 or a polypeptide as described in claim 21. A carrier comprising the isolated nucleic acid molecule as described in claim 22. A gene expression regulation system, the expression regulation system comprising: a) any of the fusion proteins of claims 1-20, the polypeptide of claim 21, the isolated nucleic acid molecule of claim 22, or the vector of claim 23; b) A gene expression regulatory cassette, comprising nucleic acid sequences encoding a target gene, a first lox site, and a second lox site, wherein the first lox site and the second lox site are oriented in the same direction and are not adjacent. According to the gene expression regulation system of claim 24, a termination element is further included between the first lox site and the second lox site, the termination element including a transcription termination sequence, a polyadenylated sequence and / or a translation repressor sequence, and different copy numbers of the above sequences. According to any one of claims 24-25, the gene expression regulation system further includes a promoter, and the gene expression regulation system comprises, from the 5' end to the 3' end, the following components in sequence: Promoter, first lox site, terminator, second lox site, and target gene. The gene expression regulation system according to any one of claims 25-26, wherein the transcription termination sequence is SEQ ID NO:
26. The gene expression regulation system according to any one of claims 24-27, wherein the nucleic acid sequences of the first lox site, the termination element, and the second lox site in the gene expression regulation cassette from the 5' end to the 3' end comprise the sequence shown in SEQ ID NO:
10. According to the gene expression regulation system of claim 24, the nucleic acid sequences of the first lox site and the second lox site are inserted into or flanking the target gene, wherein the first lox site and the second lox site contain a portion or the full length of the coding sequence of the target gene. According to the gene expression regulation system of claim 29, the coding sequence of the partial or full-length target gene includes the exon coding sequence of the target gene. According to any one of claims 24-30, the first lox site and the second lox site are independently selected from wild-type loxP sites and mutant lox sites. According to the gene expression regulation system of claim 31, the mutated lox site is selected from one or more sites in the group consisting of: LoxN site, Lox2272 site, Lox511 site, Lox5171 site, LoxM2 site, Lox66 site, and Lox71 site. Cells comprising the fusion protein of any one of claims 1-20, the polypeptide of claim 21, the isolated nucleic acid molecule of claim 22, the vector of claim 23, or the gene expression regulation system of any one of claims 24-32. The cell according to claim 33, wherein the cell comprises pluripotent stem cells, adult stem cells, immune cells, nerve cells and / or endocrine cells. The cell of claim 34, wherein the pluripotent stem cell is selected from one or more cells selected from the group consisting of embryonic stem cells (ESC), induced pluripotent stem cells (iPSC), pluripotent stem cells similar to pluripotent stem cells (PLSC), and extended pluripotent stem cells (EPSC). The cell according to claim 34, wherein the adult stem cell is selected from one or more cells selected from the group consisting of hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), neural stem cells (NSC), epidermal stem cells (EpSC), and pancreatic stem cells (PSC). The cell according to claim 34, wherein the immune cell is selected from one or more cells from the group consisting of T lymphocytes, macrophages, NK cells, NKT cells, and dendritic cells. The cell according to claim 34, wherein the endocrine cell is a pancreatic β cell. The cell according to claim 34, wherein the nerve cell is a dopamine nerve cell. A method for regulating a gene of interest, the method comprising: Add a protease inhibitor to the cells described in any one of 33-39 to regulate the activity of the fusion protein, thereby regulating the expression or silencing of the target gene. According to the method of claim 40, the protease inhibitor is an NS3 protease inhibitor selected from one or more of the following groups of inhibitors: Grazoprevir (GZV), Asunaprevir (ASV), Glecaprevir (GLE), Daclatasvir (DCV), Telaprevir (TPV), Danoprevir (DAV), Vaniprevir (VAV), Ciluprevir (BILN 2061), Simeprevir (SMV), Boceprevir (BOC), Sovaprevir (SOV), and Paritaprevir (PTV). The method according to claim 41, wherein the NS3 protease inhibitor is ASV. The method according to any one of claims 40-42 is an in vitro or ex vivo method. Use of the fusion protein of any one of claims 1-20, the polypeptide of claim 21, the isolated nucleic acid molecule of claim 22, the vector of claim 23, the gene expression regulation system of any one of claims 24-32, the cell of any one of claims 34-39, or the method of any one of claims 40-43 in the preparation of a medicament for the prevention and / or treatment of a disease. According to the use described in claim 44, the diseases include, but are not limited to, hematologic malignancies, solid tumors, autoimmune diseases, endocrine and metabolic diseases, nervous system diseases, respiratory system diseases, inflammatory diseases, and infectious diseases. According to the use of claim 45, the autoimmune disease includes, but is not limited to, systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; the endocrine disease includes, but is not limited to, diabetes; the nervous system disease includes, but is not limited to, Parkinson's disease and Alzheimer's disease; the respiratory system disease includes, but is not limited to, pneumonia and pulmonary fibrosis; and the inflammatory disease includes osteoarthritis.
